ACTINOGEN MEDICAL LIMITED
ABN 14 086 778 476
ANNUAL REPORT
YEAR ENDED 30 JUNE 2020
ACTINOGEN MEDICAL LIMITED
C O N T E N T S P A G E
ContentsPageCorporate Directory1Chairman’s Address2Corporate Governance Statement4Directors’ Report:• Information on Directors12• Operations and Financial Review16• Outlook and Business Strategy20• Remuneration Report (Audited)21Auditor’s Independence Declaration36Statement of Comprehensive Income37Statement of Financial Position38Statement of Cash Flows39Statement of Changes in Equity40Notes to the Financial Statements41Directors’ Declaration73Independent Auditor’s Report74Shareholder Information78
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E D I R E C T O R Y
1
Board of DirectorsCompany SecretaryNon-Executive Chairman – Dr Geoffrey BrookeMr Peter WebseManaging Director – Dr Bill KetelbeyNon-Executive Director – Dr George MorstynLawyersNon-Executive Director – Mr Malcolm McComasK&L GatesLevel 25 South TowerPrincipal Place of Business / Registered Office525 Collins StreetSuite 901 / Level 9Melbourne VIC 3000109 Pitt StreetSydney NSW 2000BankersNational Australia BankContact Details1232 Hay StreetTelephone: 02 8964 7401West Perth WA 6005www.actinogen.com.auABN 14 086 778 476AuditorsErnst & YoungShare RegisterErnst & Young BuildingLink Market Services11 Mounts Bay RoadLevel 12Perth WA 6000680 George StreetSydney NSW 2000Actinogen Medical Limited shares are listed on the Australia Securities Exchange ('ASX'). ASX Code: ACW
ACTINOGEN MEDICAL LIMITED
C H A I R M A N ’ S A D D R E S S
Dear Shareholder
It is with pleasure that I present to you the Annual Report for the financial year ended 30 June 2020.
With the onset of a global pandemic earlier this year, the challenges faced by the world have in many ways
been unprecedented. Throughout the health crisis Actinogen Medical has been taking the necessary health
and safety precautions to protect our staff, collaborators, study participants and the broader community.
Fortunately, since last year’s ongoing studies have largely completed, the Company’s focus has been on future
trial planning and data analysis, with the direct impact of the Covid-19 pandemic on Actinogen, being fairly
limited to date. Despite these extraordinary circumstances, Actinogen has emerged from the Covid crisis in a
strong position. We continue to carefully and prudently manage our operations and clinical development plans
to build a clear pathway towards optimising our future clinical trials and maximising value in the best interests of
our shareholders.
Late last year, Actinogen had a breakthrough with the XanaHES clinical trial. The results demonstrated a
significant improvement in cognition in healthy elderly patients dosed with Xanamem 20mg daily for 12 weeks.
This marks the first time that Xanamem has exhibited such a clear and statistically significant cognitive
improvement in human trials, while demonstrating the 20mg dose is safe and that it effectively inhibits cortisol
production. Further support for the successful development of Xanamem was demonstrated in the Target
Occupancy study, where Xanamem was shown to work as designed, and to bind to the target 11β-HDS1
enzyme in the areas of the brain considered most responsible for much of the cognitive impairment associated
with increased cortisol, across a range of disease states. These results are ground-breaking. They demonstrate
Xanamem’s proof-of-concept and confirm the significant potential for the Company to develop Xanamem for
a number of conditions presenting with cognitive impairment due to raised cortisol, including Alzheimer’s
disease.
Global Alzheimer’s disease research and development is rapidly evolving, with many objective biomarkers now
measurable in the blood - this technology was not available just a few years ago, when the Company planned
studies like XanADu. We will use this technology, as well as outcomes from our own comprehensive analysis of
the substantial dataset generated on Xanamem, to optimise patient selection and to define crucial new
outcome measures to use in the design of our future clinical studies.
Leveraging the success of the XanaHES trial and data analysis outcomes, Actinogen is planning a Phase II clinical
trial in Mild Cognitive Impairment (“MCI”) - the very early stage of Alzheimer’s disease. This is a patient population
where the disease has only just been diagnosed and where we believe there is the best opportunity for observing
a response to treatment. This study is designed to link the compelling XanaHES trial results with an Alzheimer’s
disease population, supporting our expectation that we will see a similarly strong result as we saw with XanaHES.
Alzheimer’s disease and MCI represent a huge unmet medical need and a substantial market opportunity, with
limited or no therapeutic options currently available in the market.
A detailed review of current academic and scientific research supports the exploration of new trials focusing on
cortisol inhibition, concluding that there are numerous applications in human disease for drugs that inhibit the
11β-HSD1 enzyme. This supports the ongoing development of Xanamem across a number of indications and
supports Actinogen’s strategy to broaden the development pipeline for Xanamem. This includes planning
studies in cognitive impairment associated with schizophrenia and diabetes, while also assessing other promising
opportunities.
Embracing the new Covid-driven virtual environment, Actinogen has continued to drive awareness of the
Company and Xanamem among investor and the scientific communities. Notably, with key findings from the
latest data generated on Xanamem presented virtually at the AAT-AD/PD international Focus Meeting 2020.
Our participation in medical and scientific conferences like this, as well as numerous partnering and investor
meetings, play a pivotal role in driving awareness of, and shaping further strategic opportunities for, our clinical
development.
While the ongoing health crisis has caused disruption across our industry and there remains uncertainty around
the duration of the pandemic related restrictions, we remain confident in our ability to navigate these
challenges as they arise. With a strong capital position and pleasing progress made with planning for our new
2
ACTINOGEN MEDICAL LIMITED
C H A I R M A N ’ S A D D R E S S
clinical trials, we look forward to commencing the planned trials in the months ahead, and to rapidly progressing
the development of Xanamem.
I would also like to take this opportunity to thank all our shareholders for their continued support of the
Company’s endeavours, our staff and partners for their ongoing hard work and dedication as well as to my
fellow Board members for their commitment to Actinogen Medical Limited.
Dr Geoff Brooke
Chairman
Wednesday, 26 August 2020
3
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
_____________________________________________________________
This Corporate Governance Statement (“Statement”) outlines the key aspects of Actinogen Medical
Limited’s (“Actinogen Medical” or “the Company”) governance framework and main governance
practices. The Company’s charters, policies, and procedures are regularly reviewed and updated to
comply with law and best practice. These charters and policies can be viewed on Actinogen
Medical’s website located at www.actinogen.com.au.
This Statement is structured with reference to the Australian Securities Exchange (“ASX”) Corporate
Governance Council’s (“the Council’s”) “Corporate Governance Principles and Recommendations
3rd Edition” (“the Recommendations”). The Company will be reporting against the “Corporate
Governance Principles and Recommendations 4th Edition” for the financial year ending 30 June 2021.
The Board of Directors has adopted the Recommendations to the extent that is deemed appropriate
considering the current size and operations of the Company. Therefore, considering the size and
financial position of the Company, where the Board considers that the cost of implementing a
Recommendation outweighs any potential benefits, those Recommendations have not been
adopted.
This Statement was approved by the Board of Directors and is current as at 26 August 2020.
Principle 1: Lay solid foundations for management and oversight
Roles of the Board & Management
The Board is responsible for evaluating and setting the strategic direction for the Company, establishing
goals for management and monitoring the achievement of these goals. The Managing Director is
responsible to the Board for the day-to-day management of the Company.
The principal functions and responsibilities of the Board include, but are not limited to, the following:
• Appointment, evaluation and, if necessary, removal of the Managing Director, any other Executive
Directors, the Company Secretary and the Chief Financial Officer (if applicable) and approval of
their remuneration,
• Determining, in conjunction with management, corporate strategy, objectives, operations, plans
and approving and appropriately monitoring plans, new investments, major capital and operating
expenditures, capital management, acquisitions, divestitures and major funding activities,
• Establishing appropriate levels of delegation to the Managing Director to allow the business to be
managed efficiently,
• Approval of remuneration methodologies and systems,
• Monitoring actual performance against planned performance expectations and reviewing
operating information at a requisite level to understand at all times the financial and operating
conditions of the Company,
• Monitoring the performance of senior management, including the implementation of strategy and
•
ensuring appropriate resources are available,
Identifying areas of significant business risk and ensuring that the Company is appropriately
positioned to manage those risks,
• Overseeing the management of safety, occupational health and environmental issues,
• Satisfying itself that the financial statements of the Company fairly and accurately set out the
financial position and financial performance of the Company for the period under review,
• Satisfying itself that there are appropriate reporting systems and controls in place to assure the
Board that proper operational, financial, compliance, risk management and internal control
processes are in place and functioning appropriately,
• Ensuring that appropriate internal and external audit arrangements are in place and operating
effectively,
• Authorising the issue of any shares, options, equity instruments or other securities within the
constraints of the Corporations Act and the ASX Listing Rules, and
4
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
_____________________________________________________________
• Ensuring that the Company acts legally and responsibly on all matters and assuring itself that the
Company has adopted, and that its practice is consistent with, a number of guidelines including:
− Code of Conduct
− Continuous Disclosure Policy
− Diversity Policy
− Performance Evaluation Policy
− Procedures for Selection and Appointment of Directors
− Remuneration Policy
− Risk Management and Internal Compliance and Control Policy
− Securities Trading Policy
− Shareholder Communications Policy
Subject to the specific authorities reserved to the Board under the Board Charter, the Board has
delegated to the Managing Director responsibility for the management and operation of Actinogen
Medical. The Managing Director is responsible for the day-to-day operations, financial performance
and administration of Actinogen Medical within the powers authorised to him from time-to-time by the
Board. The Managing Director may make further delegation within the delegations specified by the
Board and is accountable to the Board for the exercise of those delegated powers.
Further details of Board responsibilities, objectives and structure are set out in the Board Charter on the
Actinogen Medical website.
Board Committees
The Board considers that the Company is not currently of a size, nor are its affairs of such complexity to
justify the formation of separate committees at this time, including Audit, Risk, Remuneration or
Nomination Committees, preferring at this stage, to manage the Company through the full Board of
Directors. The Board assumes the responsibilities normally delegated to the Audit, Risk, Remuneration
and Nomination Committees.
If the Company’s activities increase, in size, scope and nature, the appointment of separate
committees will be reviewed by the Board and implemented if appropriate.
Board Appointments
The Company undertakes comprehensive reference checks prior to appointing a Director, or putting
that person forward as a candidate to ensure that person is competent, experienced, and would not
be impaired in any way from undertaking the duties of Director. The Company provides relevant
information to shareholders for their consideration about the attributes of candidates together with
whether the Board supports the appointment or re-election.
The terms of the appointment of a Non-Executive Director, Executive Director and senior executives
are agreed upon and set out in writing at the time of appointment.
The Company Secretary
The Company Secretary is accountable directly to the Board, through the Chairman, on all matters to
do with the proper functioning of the Board, including agendas, Board papers and minutes, advising
the Board and its Committees (as applicable) on governance matters, monitoring that the Board and
Committee policies and procedures are followed, communication with regulatory bodies and the ASX
and statutory and other filings.
Diversity
The Company has adopted a formal Diversity Policy. However, the Company is currently in an early
stage of its development and given that it currently has a limited number of employees, the application
of measurable objectives in relation to gender diversity, at various levels of the Company’s business, is
not considered to be appropriate nor practical.
The Board will review this position on an annual basis and will implement measurable objectives as and
when it deems the Company to require them.
5
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
_____________________________________________________________
The proportion of women in the entity as at 26 August 2020 is as follows:
Women on the Board: 0 of 4 (0%)
Women in senior executive positions: 1 of 2 (50%)
Women in the organisation: 5 of 11 (45%)
The Company’s Diversity Policy is available on its website.
Board & Management Performance Review
On an annual basis, the Board conducts a review of its structure, composition and performance.
The annual review includes consideration of the following measures:
• comparing the performance of the Board against the requirements of its Charter,
• assessing the performance of the Board over the previous 12 months having regard to the
corporate strategies, operating plans and the annual budget,
reviewing the Board’s interaction with management,
reviewing the type and timing of information provided to the Board by management,
reviewing management’s performance in assisting the Board to meet its objectives, and
identifying any necessary or desirable improvements to the Board Charter.
•
•
•
•
The method and scope of the performance evaluation will be set by the Board and may include a
self-assessment checklist to be completed by each Director. The Board may also use an independent
adviser to assist in the review.
The Chairman has primary responsibility for conducting performance appraisals of Non-Executive
Directors, in conjunction with them, having particular regard to:
• contribution to Board discussion and function,
• degree of independence including relevance of any conflicts of interest,
• availability for and attendance at Board meetings and other relevant events,
• contribution to Company strategy,
• membership of and contribution to any Board committees, and
•
suitability to Board structure and composition.
The Board conducts an annual performance assessment of the Managing Director against agreed key
performance indicators.
Board and management performance reviews were conducted during the year in accordance with
the above processes.
Independent Advice
Directors have a right of access to all Company information and executives. Directors are entitled, in
fulfilling their duties and responsibilities, to obtain independent professional advice on any matter
connected with the discharge of their responsibilities, with prior notice to the Chairman, at Actinogen
Medical’s expense.
Principle 2: Structure the Board to add value
Board Composition
During the financial year, and to the date of this Report, the Board was comprised of the following
members:
Dr Geoffrey Brooke
Dr Bill Ketelbey
Dr George Morstyn
Mr Malcolm McComas
Non-Executive Chairman (appointed 1 March 2017)
Managing Director (appointed 18 December 2014)
Non-Executive Director (appointed 1 December 2017)
Non-Executive Director (appointed 4 April 2019)
6
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
_____________________________________________________________
The Company currently has one Executive Director, the Managing Director, and three Non-Executive
Directors. The Board is currently comprised of a majority of independent Directors, being Dr Geoffrey
Brooke (the Company’s Non-Executive Chairman), Mr Malcolm McComas, and Dr George Morstyn.
Actinogen Medical has adopted a definition of 'independence' for Directors that is consistent with the
Recommendations.
Board Selection Process
The Board considers that a diverse range of skills, backgrounds, knowledge and experience is required
in order to effectively govern Actinogen Medical. The Board believes that orderly succession and
renewal contributes to strong corporate governance and is achieved by careful planning and
continual review.
The Board is responsible for the nomination and selection of Directors. The Directors review the size and
composition of the Board regularly and at least once a year as part of the Board evaluation process.
The Board has a skills matrix covering the competencies and experience of each member. When the
need for a new Director is identified, the required experience and competencies of the new Director
are defined in the context of this matrix and any gaps that may exist.
Generally a list of potential candidates is identified based on these skills required and other issues such
as geographic location and diversity criteria. Candidates are assessed against the required skills and
on their qualifications, backgrounds and personal qualities. In addition, candidates are sought who
have a proven track record in creating security holder value and the required time to commit to the
position.
Induction of New Directors and Ongoing Development
New Directors are issued with a formal Letter of Appointment that sets out the key terms and conditions
of their appointment, including Director's duties, rights and responsibilities, the time commitment
envisaged, and the Board's expectations regarding involvement with any Committee work.
An induction program is in place and new Directors are encouraged to engage in professional
development activities to develop and maintain the skills and knowledge needed to perform their role
as Directors effectively.
Principle 3: Act ethically and responsibly
The Company has implemented a Code of Conduct, which provides guidelines aimed at maintaining
high ethical standards, corporate behaviour and accountability within the Company.
respect the law and act in accordance with it,
All employees and Directors are expected to:
•
• maintain high levels of professional conduct,
•
• avoid real or perceived conflicts of interest,
• act in the best interests of shareholders,
• by their actions contribute to the Company’s reputation as a good corporate citizen which seeks
respect confidentiality and not misuse Company information, assets or facilities,
the respect of the community and environment in which it operates,
• perform their duties in ways that minimise environmental impacts and maximise workplace safety,
• exercise fairness, courtesy, respect, consideration and sensitivity in all dealings within their
workplace and with customers, suppliers and the public generally, and
• act with honesty, integrity, decency and responsibility at all times.
An employee that breaches the Code of Conduct may face disciplinary action including, in the case
of a serious breach, dismissal. If an employee suspects that a breach of the Code of Conduct has
occurred, or will occur, he or she must report that breach to the Company Secretary. No employee
will be disadvantaged or prejudiced if he or she reports in good faith a suspected breach. All reports
will be acted upon and kept confidential.
7
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
_____________________________________________________________
Principle 4: Safeguard integrity in corporate reporting
The Board as a whole fulfills the functions normally delegated to the Audit Committee as detailed in
the Audit Committee Charter.
The Board is responsible for the initial appointment of the external auditor and the appointment of a
new external auditor when any vacancy arises. Candidates for the position of external auditor must
demonstrate complete independence from the Company through the engagement period. The
Board may otherwise select an external auditor based on criteria relevant to the Company’s business
and circumstances. The performance of the external auditor is reviewed on an annual basis by the
Board.
The Board receives regular reports from management and from external auditors. It also meets with
the external auditors as and when required.
The external auditors attend Actinogen Medical's Annual General Meeting (“AGM”) and are available
to answer questions from security holders relevant to the audit.
Prior approval of the Board must be gained for non-audit work to be performed by the external auditor.
There are qualitative limits on this non-audit work to ensure that the independence of the auditor is
maintained.
There is also a requirement that the audit partner responsible for the audit not perform in that role for
more than five years.
Chief Executive Officer (“CEO”) & Chief Financial Officer (“CFO”) Certifications
The Board has received certifications from the CEO and CFO Equivalent in connection with the
financial statements for Actinogen Medical for the reporting period. The certifications state that the
declaration provided in accordance with Section 295A of the Corporations Act as to the integrity of
the financial statements is founded on a sound system of risk management and internal control which
is operating effectively.
Principle 5: Make timely and balanced disclosure
The Company has a Continuos Disclosure Policy which outlines the disclosure obligations of the
Company as required under the ASX Listing Rules and the Corporations Act. The policy is designed to
ensure that procedures are in place so that the market is properly informed of matters which may have
a material impact on the price at which Company securities are traded.
The Board considers whether there are any matters requiring disclosure in respect of each and every
item of business that it considers in its meetings. Individual Directors are required to make such a
consideration when they become aware of any information in the course of their duties as a Director
of the Company.
The Company is committed to ensuring all investors have equal and timely access to material
information concerning the Company.
The Board has designated the Company Secretary as the person responsible for communicating with
the ASX. The Chairman, Managing Director and the Company Secretary are responsible for ensuring
that:
a) Company announcements are made in a timely manner, that announcements are factual and
do not omit any material information required to be disclosed under the ASX Listing Rules and the
Corporations Act, and
b) Company announcements are expressed in a clear and objective manner that allows investors
to assess the impact of the information when making investment decisions.
8
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
_____________________________________________________________
Principle 6: Respect the rights of security holders
The Company recognises the value of providing current and relevant information to its shareholders.
The Company respects the rights of its shareholders and to facilitate the effective exercise of those
rights the Company is committed to:
• communicating effectively with shareholders through releases to the market via the ASX, the
Company’s website, information emailed or mailed to shareholders and the general meetings of
the Company,
• giving shareholders ready access to clear and understandable information about the Company,
and
• making it easy for shareholders to participate in general meetings of the Company.
The Company also makes available a telephone number and email address for shareholders to make
enquiries of the Company. These contact details are available on the “contact us” page of the
Company’s website.
Shareholders may elect to, and are encouraged to, receive communications from Actinogen Medical
and Actinogen Medical's securities registry electronically.
The Company maintains information in relation to its Constitution, governance documents, Directors
and senior executives, Board and committee charters, annual reports and ASX announcements on the
Company’s website.
Principle 7: Recognise and manage risk
The Board is committed to the identification, assessment and management of risk throughout
Actinogen Medical's business activities.
The Board is responsible for the oversight of the Company’s risk management and internal compliance
and control framework. Responsibility for control and risk management is delegated to the
appropriate level of management within the Company with the Managing Director having ultimate
responsibility to the Board for the risk management and internal compliance and control framework.
Actinogen Medical has established policies for the oversight and management of material business
risks.
Actinogen Medical's Risk Management and Internal Compliance and Control Policy recognises that
risk management is an essential element of good corporate governance and fundamental in
achieving its strategic and operational objectives. Risk management improves decision making,
defines opportunities and mitigates material events that may impact security holder value.
Actinogen Medical believes that explicit and effective risk management is a source of insight and
competitive advantage. To this end, Actinogen Medical is committed to the ongoing development
of a strategic and consistent enterprise-wide risk management program, underpinned by a risk
conscious culture.
Actinogen Medical accepts that risk is a part of doing business. Therefore, the Company’s Risk
Management and Internal Compliance and Control Policy is not designed to promote risk avoidance.
Rather Actinogen Medical's approach is to create a risk conscious culture that encourages the
systematic identification, management and control of risks whilst ensuring the Company does not enter
into unnecessary risks or enter into risks unknowingly.
Actinogen Medical assesses its risks on a residual basis, that is, it evaluates the level of risk remaining
and considering all the mitigation practices and controls. Depending on the materiality of the risks,
Actinogen Medical applies varying levels of management plans.
9
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
_____________________________________________________________
The Board has required management to design and implement a risk management and internal
compliance and control system to manage Actinogen Medical's material business risks. It receives
regular reports on specific business areas where there may exist significant business risk or exposure.
The Company faces risks inherent to its business, including economic risks, which may materially impact
the Company’s ability to create or preserve value for security holders over the short, medium or long
term. The Company has in place policies and procedures, including a risk management framework
(as described in the Company’s Risk Management and Internal Compliance and Control Policy),
which is developed and updated to help manage these risks. The Board does not consider that the
Company currently has any material exposure to environmental or social sustainability risks.
The Company’s process of risk management and internal compliance and control includes:
•
identifying and measuring risks that might impact upon the achievement of the Company’s goals
and objectives and monitoring the environment for emerging factors and trends that affect those
risks,
formulating risk management strategies to manage identified risks and designing and implementing
appropriate risk management policies and internal controls, and
•
• monitoring the performance of, and improving the effectiveness of, risk management systems and
internal compliance and controls, including regular assessment of the effectiveness of risk
management and internal compliance and control.
The Board reviews the Company’s risk management framework at least annually to ensure that it
continues to effectively manage risk.
Management reports to the Board as to the effectiveness of Actinogen Medical's management of its
material business risks at each meeting.
Principle 8: Remunerate fairly and responsibly
Actinogen Medical’s Remuneration Policy was designed to recognise the competitive environment
within which Actinogen Medical operates and also emphasise the requirement to attract and retain
high calibre talent in order to achieve sustained improvement in Actinogen Medical’s performance.
The overriding objective of the Remuneration Policy is to ensure that an individual’s remuneration
package accurately reflects their experience, level of responsibility, individual performance and the
performance of Actinogen Medical.
The key principles are to:
link executive reward with strategic goals and sustainable performance of Actinogen Medical,
•
• apply challenging corporate and individual key performance indicators that focus on both short-
term and long-term outcomes,
• motivate and recognise superior performers with fair, consistent and competitive rewards,
•
•
•
remunerate fairly and competitively in order to attract and retain top talent,
recognise capabilities and promote opportunities for career and professional development, and
through employee ownership of Actinogen Medical shares, foster a partnership between
employees and other security holders.
The Board determines the Company’s remuneration policies and practices and assesses the necessary
and desirable competencies of Board members. The Board is responsible for evaluating Board
performance, reviewing Board and management succession plans and determines remuneration
packages for the CEO, Non-Executive Directors and senior management based on an annual review.
Actinogen Medical’s executive remuneration policies and structures and details of remuneration paid
to Directors and senior managers are set out in the Remuneration Report.
Non-Executive Directors receive fees (including statutory superannuation where applicable) for their
services, the reimbursement of reasonable expenses and, in certain circumstances, options. They do
not receive any termination or retirement benefits, other than statutory superannuation.
10
ACTINOGEN MEDICAL LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
_____________________________________________________________
The maximum aggregate remuneration approved by shareholders for Non-Executive Directors is
$500,000 per annum. The Directors set the individual Non-Executive Directors fees within the limit
approved by shareholders. The total fees paid to Non-Executive Directors during the reporting period
was $224,560.
Executive Directors and other senior executives are remunerated using combinations of fixed and
performance-based remuneration. Fees and salaries are set at levels reflecting market rates and
performance-based remuneration is linked directly to specific performance targets that are aligned to
both short and long-term objectives.
In accordance with the Company’s Securities Trading Policy, participants in an equity based incentive
scheme are prohibited from entering into any transaction that would have the effect of hedging or
otherwise transferring the risk of any fluctuation in the value of any unvested entitlement in the
Company’s securities to any other person.
Further details in relation to the Company’s remuneration policies are contained in the Remuneration
Report, within the Directors’ Report.
11
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
Your Directors present their report pertaining to Actinogen Medical Limited (‘Actinogen Medical’ or ‘the
Company’) for the year ended 30 June 2020.
➢
INFORMATION ON DIRECTORS
BOARD OF DIRECTORS
1.
The names and details of the Company’s Directors in office during the financial year and until the date of this
Report are as follows. Directors were in office for the entire period, unless otherwise stated. The were no Director
resignations that occurred during the year ended 30 June 2020.
Dr Geoffrey Brooke (appointed 1 March 2017)
MBBS, MBA
Non-Executive Chairman
Dr Brooke is a healthcare industry and venture capital veteran with over 30 years’ international experience as
the founder, lead investor and/or Chairman/Director of numerous healthcare companies with a realised value
of more than $1.5 billion. Most notably, he was the Managing Director and Founder of leading life sciences
venture capital firm, GBS Ventures - one of Asia Pacific’s premier investors in the healthcare space. There, Dr
Brooke was responsible for GBS’s healthcare venture activity in the region and raised $450 million in venture and
private equity funds, focused on biopharmaceuticals, medical devices and services.
Dr Brooke was also responsible for numerous investments and exits via NASDAQ and ASX public listings and
trade sales, as well as being lead investor in numerous investments syndicated in multiple rounds with premier
US venture firms. Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm,
Medvest Inc., with investors including the venture capital arm of leading global multinational medical devices,
pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Medvest was focused on
founding companies based upon healthcare-related technology, including pharmaceuticals, biotechnology,
therapeutic devices, medical services and information systems.
Dr Brooke now acts as a private investor in, and independent director for, a number of small to medium-sized
Australian and US private and public companies. He holds a Bachelor of Medicine and a Bachelor of Surgery
from Melbourne University (Australia) and a Masters of Business Administration from IMEDE (Switzerland), now
IMD.
During the past three years Dr Brooke has served as a Director of the following ASX-listed companies:
• Non-Executive Director of Acrux Limited (ASX:ACR) – Current
• Non-Executive Chairman of Cynata Therapeutics Limited (ASX:CYP) – Current
Dr Bill Ketelbey (appointed 18 December 2014)
MBBCh, FFPM, MBA, GAICD
Managing Director and Chief Executive Officer
Dr Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional, with
more than 30 years’ experience in the industry, including senior medical and management roles with global
pharmaceutical giant, Pfizer. Dr Ketelbey has a medical degree from the University of the Witwatersrand (South
Africa), is a Fellow of the Faculty of Pharmaceutical Medicine with the Royal College of Physicians (UK), has an
MBA from Macquarie University (Australia), and is a Graduate of the Australia Institute of Company Directors.
12
NamePositionAppointedResignedDr Geoffrey BrookeNon-Executive Chairman1/03/2017CurrentDr Bill KetelbeyManaging Director / Chief Executive Officer18/12/2014CurrentDr George MorstynNon-Executive Director1/12/2017CurrentMr Malcolm McComasNon-Executive Director4/04/2019Current
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
Prior to joining Actinogen Medical, Dr Ketelbey was the APAC Regional Vice President of Medical Affairs for
Pfizer’s Primary Care Business Unit and Country Medical Director for Pfizer, Australia and New Zealand. At Pfizer,
Dr Ketelbey was responsible for leading the development of numerous medicines across a broad range of
therapeutic areas, including Aricept, the market-leading therapy for Alzheimer’s disease.
Dr Ketelbey is a Non-Executive Director of the Westmead Institute of Medical Research (WIMR) and chairs
the IP and Commercialisation Committee of WIMR.
Dr Ketelbey has held no other ASX-listed directorships during the past three years.
Dr George Morstyn (appointed 1 December 2017)
MBBS FRACP PhD FTSE
Non-Executive Director
Dr Morstyn has more than 25 years’ experience in the biotechnology industry including as Senior Vice
President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had overall responsibility
globally for drug development in all therapeutic areas including neuroscience at Amgen Inc. and was a
member of the Operating Committee. Many new products were approved and launched during Dr
Morstyn’s tenure. Prior to joining Amgen Inc. Dr Morstyn was the principal investigator on the earliest clinical
studies of the haemopoietic colony stimulating factors (‘CSFs’). The CSFs were subsequently approved and
launched and were a major medical breakthrough that have been used to reduce side effects of
chemotherapy and enable transplantation in more than 20 million patients worldwide. The CSFs have
become multi-billion dollar drugs. Since returning to Australia, Dr Morstyn has been a Non-Executive Director
of various for-profit and not-for-profit companies, including many biotechnology companies.
Dr Morstyn is a medical graduate of Monash University (Australia), and obtained a PhD at the Walter and
Eliza Hall Institute of Medical Research (Australia) and a FRACP in Medical Oncology following a Fellowship
at the National Cancer Institute in the USA. He is currently an advisor to Symbio (Tokyo) Limos Biotech and
TroBio. He is a Member of the Australian Institute of Company Directors and a Fellow of the Australian
Academy of Technological Sciences and Engineering.
Dr Morstyn has held no other ASX-listed directorships during the past three years.
Mr Malcolm McComas (appointed 4 April 2019)
BEc, LLB (Monash), SFFin, FAIDC
Non-Executive Director
Mr McComas brings 30 years of experience in financial services covering corporate finance, mergers and
acquisitions, debt and equity funding transactions across multiple industry sectors. He previously held
leadership roles with Grant Samuel, County NatWest (now Citigroup) and Morgan Grenfell (now Deutsche
Bank) in Australia and the UK. Previously, Mr McComas was a lawyer at Herbert Geer specialising in tax.
Mr McComas is an experienced public company director and the for-profit area as a director of the
Australasian Leukemia and Lymphoma Group. He is a Fellow of the Australian Institute of Company
Directors and holds degrees in Law and Economics from Monash University (Australia).
During the past three years Mr McComas has served as a Director of the following ASX-listed companies:
• Chairman of Pharmaxis Limited (ASX:PXS) – Current
• Chairman of Fitzroy River Corporation Limited (ASX:FZR) – Current
• Non-Executive director of Core Lithium Limited (ASX:CXO) – Current
• Non-Executive Director of Royalco Resources Limited (ASX:RCO) – Delisted February 2020
• Non-Executive Director of Saunders International (ASX:SND) - Resigned May 2019
13
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
Interests in the shares and options of the Company and related bodies corporate
As at the date of this Report, the interests of the Directors in the shares and options of the Company were as
follows:
(a) Of Dr Ketelbey’s fully paid ordinary shareholding, 9 million shares were previously LTI Rights (“loan shares”) that have
fully vested and were paid for during the financial year ended 30 June 2020.
2. DIRECTORS’ MEETINGS
The following table sets out the number of meetings of the Company’s Directors held while each Director was
in office and the number of meetings attended by each Director.
Due to size and scale of the Company, there are no Remuneration, Risk, Nomination or Audit Committees at
present. Matters typically dealt with by these Committees are, for the time being, referred to the Board of
Directors. For details of the function of the Board please refer to the Corporate Governance Statement which
is included as part of this Annual Report.
3. COMPANY SECRETARY
Peter Webse (appointed 10 October 2013)
B.Bus, FGIA, FCPA, MAICD
Mr Webse has over 27 years’ company secretarial experience and is a Director of Governance Corporate
Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate
advisory services. Mr Webse holds a Bachelor of Business with a double major in Accounting and Finance, is
a Fellow of the Governance Institute of Australia, a Fellow Certified Practicing Accountant and a Member of
the Australian Institute of Company Directors.
4. CORPORATE GOVERNANCE
The Board recognises the recommendations of the ASX Corporate Governance Council and has disclosed its
level of compliance with those guidelines within the Corporate Governance Statement which is included as
part of this Annual Report.
14
DirectorFully paid ordinary sharesTotal unlisted optionsDr Geoffrey Brooke1,325,000 9,900,000 Dr Bill Ketelbey (a)9,953,803 11,700,000 Dr George Morstyn200,000 3,000,000 Mr Malcolm McComas500,000 3,000,000 Total11,978,803 27,600,000 DirectorNumber of meetings available to attendNumber of meetings attendedDr Geoffrey Brooke88Dr Bill Ketelbey88Dr George Morstyn88Mr Malcolm McComas88
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
5.
SHARES UNDER OPTION
As at the date of this Report, there were 41,942,631 unissued ordinary shares under option:
(a) These options were issued to Dr Geoffrey Brooke as part of his appointment as Non-Executive Chairman of the
Company on 1 March 2017.
(b) These options were issued to Dr George Morstyn as part of his appointment as Non-Executive Director of the
Company on 1 December 2017.
(c) Of the 18,100,000 options issued, 4,900,000 options were issued to Dr Geoffrey Brooke, 11,700,000 options were
issued to Dr Bill Ketelbey and 1,500,000 options were issued to Dr George Morstyn.
(d) These options were issued to a Consultant.
(e) These options were issued to Mr Malcolm McComas as part of his appointment as Non-Executive Director of the
Company on 4 April 2019.
During the year, and up to the date of this Report, there were no options that were exercised, expired, lapsed
or forfeited.
LTI Rights, although are accounted for as “in-substance options” due to the vesting conditions attached to
them, they are in fact issued ordinary shares and therefore, not included in the table above. For further
information on LTI Rights on issue or lapsed during the year, refer to Section 3C(iii) of the Remuneration Report.
15
QuantityTypeGrant DateExercise PriceExpiry DateVesting ConditionsComment2,100,000 Employee Options (A) (Tranche 1)23/01/20170.100$ 5/02/2021Yes - fully vested5,000,000 Director Options (G)24/03/20170.100$ 24/03/2025Yes - fully vested(a)417,188 Employee Options (B) (Tranche 2)12/07/20170.100$ 5/02/2021Upfront vesting1,500,000 Director Options (D)18/01/20180.100$ 1/12/2022Yes(b)417,110 Employee Options (C) (Tranche 3)20/03/20180.100$ 5/02/2021Upfront vesting625,000 Employee Options (C) (Tranche 3)20/03/20180.100$ 5/02/2021Yes - fully vested18,100,000 Director Options (F)28/11/20180.085$ 27/11/2023Yes(c)5,783,333 Employee Options (E) (Tranche 4)12/12/20180.085$ 12/12/2023Yes5,000,000 Consultant Options1/02/20190.093$ 1/02/2024Yes(d)3,000,000 Director Options (H)4/04/20190.100$ 4/04/2024Yes(e)41,942,631 Total shares under option
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
➢ OPERATIONS AND FINANCIAL REVIEW
PRINCIPAL ACTIVITIES
6.
The principal activity of the Company during the year focussed on the ongoing development of Xanamem,
a novel treatment for cognitive impairment due to raised cortisol that is associated with a number of
neurological and metabolic diseases including Alzheimer’s disease.
7.
REVIEW OF OPERATIONS
Highlights for the Financial Year
(i) XanaHES Phase I Clinical Trial - breakthrough results with cognitive improvement demonstrated
(ii) Phase I Target Occupancy study – demonstrates that Xanamem works as designed
(iii) Comprehensive review of Xanamem™ dataset - optimising parameters for future clinical trials
(iv) Progressing plans for multiple clinical trials - including for MCI due to Alzheimer’s disease
(v) Raising awareness - attendance at various conferences and industry partnering meetings
(vi) Strategy to broaden pipeline - supported by article accepted for publishing in peer reviewed journal
(vii) Other - pre-clinical and toxicology studies
(i)
XanaHES Phase I Clinical Trial – breakthrough results with cognitive improvement demonstrated
In October 2019, the results from the XanaHES (Xanamem™ in Healthy Elderly Subjects) trial demonstrated
a statistically significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for
12 weeks, as compared to placebo. The trial was primarily designed to investigate the safety of a 20mg
dose, but also included an exploratory assessment of cognition to evaluate the cognitive efficacy of
Xanamem using an industry standard Cogstate Neuropsychological Test Battery (NTB). Results from the study
showed cognitive improvement in three of the six domains of cognition evaluated and that Xanamem
significantly reduced serum cortisol levels in trial participants. These results support the cortisol hypothesis
underpinning the discovery and development of Xanamem. Furthermore, Xanamem 20mg daily exhibited
a good safety profile over the 12 weeks of treatment, with no serious adverse events reported.
This is the first clinical trial where Xanamem has demonstrated such clear and statistically significant
cognitive improvement in humans. Previously, the XanADu trial in mild Alzheimer's patients showed that
Xanamem 10mg daily was safe and suppressed cortisol production but did not generate a statistically
significant improvement in cognition. The positive and robust efficacy results from the XanaHES trial suggests
that the XanADu dosing was suboptimal, and the XanaHES data substantially enhances the Xanamem
dataset, helping to shape Actinogen's drug development strategy for the treatment of Alzheimer's disease
and other neurological and metabolic diseases associated with cognitive impairment.
(ii)
Phase I Target Occupancy study – demonstrates that Xanamem works as designed
The Phase I Target Occupancy study was designed to measure the effectiveness of different Xanamem
doses on binding to the 11β-HSD1 enzyme in the brain. Results from both Alzheimer's patients and cognitively
normal healthy volunteers studied in the trial have demonstrated that doses of Xanamem between 5mg to
30mg daily effectively block the 11β-HSD1 enzyme in the brain.
This confirms that Xanamem works as designed. It crosses the blood-brain-barrier and effectively binds to
the target 11β-HSD1 enzyme in the brain, most particularly in the areas of brain considered responsible for
much of the cognitive impairment associated with increased cortisol production.
16
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
Due to the global Covid-19 pandemic, enrolment for the final few patients has been suspended until further
notice, in-line with directives from ethics committees, regulators, and hospital administrators that patient
safety and well-being must take precedence. This study has progressed well, with 32 out of 36 patients
having completed the trial, providing adequate data to feed into key data analyses currently underway.
We expect to enroll the final four patients to complete this study once we are able to recommence
enrollment.
(iii)
Comprehensive review of Xanamem™ dataset - optimising parameters for future clinical trials
Actinogen and its consultants and advisors are in the process of finalising a comprehensive analysis of the
substantial Xanamem dataset generated from numerous Xanamem studies including XanADu, XanaHES
and the PET Target Occupancy study. The output from this detailed data modelling and analysis will provide
important insights into Xanamem pharmacology, dosing, and patient characteristics that will help inform
and optimise the study design for the new clinical trials.
(iv)
Progressing plans for multiple clinical trials - including for MCI due to Alzheimer’s disease
Leveraging the substantial dataset for Xanamem and the successful efficacy outcome of the XanaHES
study, Actinogen is planning to trial Xanamem in patients with Mild Cognitive Impairment (MCI), the very
early stages of cognitive decline due to Alzheimer’s disease. We expect that a study in MCI due to
Alzheimer’s disease, will link the positive XanaHES trial efficacy and safety results with an Alzheimer’s disease
patient population. Alzheimer’s disease research and development is evolving globally with many new
biomarkers emerging in recent years that are measurable in the blood. Actinogen will leverage this
breakthrough technology to optimise patient selection and strengthen the efficacy evaluation in the MCI
and other future Xanamem trials.
Actinogen is also targeting trials in cognitive impairment associated with schizophrenia and diabetes, and
exploring and assessing additional development opportunities as they arise. The Company has continued
to make a range of grant applications to support the funding of these studies and continues discussions
with key advisors and regulators to advance and optimise these trial plans.
(v)
Raising awareness - attendance at various conferences and industry partnering meetings
During the year, the Company continued discussions with potential collaborators and commercial partners,
presenting at numerous investor, biotech, and industry conferences, including:
•
June 2020: BIO Digital - Virtual
• April 2020: Advancement in Alzheimer's and Parkinson's Therapies Focus Meeting (AAT-AD/PD)- Virtual
o
The recorded presentation can be found on Actinogen’s website: www.actinogen.com.au
January 2020: 3rd Annual SACHS Neuroscience Innovation Forum – San Francisco
January 2020: Participation in numerous partnering meetings during JP Morgan Week – San Francisco
•
•
• December 2019: Clinical Trial on Alzheimer’s Disease (CTAD)- San Diego
• October 2019: Australia Biotech Invest and Partnering Conference – Melbourne
• October 2019: AusBiotech - Melbourne
• October 2019: Australian Microcap Investment Conference - Melbourne
• October 2019: AC4R Annual Scientific Meeting – Sydney
• August 2019: Bio Connections Australia – Melbourne
•
Jul 2019: Bioshares Biotech Summit
17
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
(vi)
Actinogen strategy supported by article published in peer-reviewed journal
A comprehensive review of the published scientific 11β-HSD1 literature led by Actinogen collaborator, Dr
Sarah Gregory, was published on 20 April 2020 in the peer-reviewed journal Metabolism: Clinical and
Experimental. The review concludes that there are many potential applications in human disease for drugs
that inhibit the 11β-HSD1 enzyme. This is a growing area of research, and future studies should focus on
gaining more understanding into the complex relationship between the 11β-HSD1 enzyme and disease
pathology. This publication supports the ongoing clinical development of Xanamem across multiple
indications.
(vii)
Other Pre-Clinical and Toxicology Studies
The pre-clinical long-term toxicology studies are progressing well, with no substantial safety or long-term
toxicity issues reported. These studies are required by regulatory authorities to commence human studies
with dosing durations beyond 12 weeks. Additionally, Actinogen has sponsored other pre-clinical studies
focusing on pharmacokinetic, pharmacodynamic and mechanistic analyses of Xanamem in vitro, to
complement the substantial clinical dataset that has been generated to date.
All of the pre-clinical studies, being conducted in the UK and France, experienced minor impacts due to
Covid-19 restrictions, primarily due to the global directive that employees work from home. These restrictions
have since been lifted and work recommenced.
8.
FINANCIAL PERFORMANCE
The financial performance of the Company during the year ended 30 June 2020 is as follows:
(a) The Company recognised $94,057 in interest income from ordinary activities and $3,516,397 in other
income of which: $2,482,699 relates to a research and development rebate for the 2020 financial year
that has been raised as a receivable at year end, $201,272 relates to government grants received
during the year, and the remaining $832,426 relates to prior period R&D rebates recognised as income
in the current financial year.
18
Full-year endedFull-year ended30/06/202030/06/2019Revenue and other income ($)(a)3,610,4545,067,301Net loss after tax ($)(5,330,529)(9,887,682)Loss per share (cents)(0.48)(0.90)Dividend ($) - -
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
9.
FINANCIAL POSITION
The financial position of the Company as at 30 June 2020 is as follows:
(a) For further information on movements in cash, refer to Note 8 of the financial statements.
(b) For further information on movements in equity, refer to Note 13 of the financial statements.
10. SHARE PRICE PERFORMANCE
The table below sets out the performance of the Company and the consequences of performance on
shareholders’ wealth over the past five years:
11. DIVIDENDS
No amounts have been paid or declared by way of dividend since the date of incorporation. The Directors
recommend that no final dividend be paid.
12. EVENTS SUBSEQUENT TO THE END OF THE FINANCIAL YEAR
Other than what is stated below, there are no matters or circumstances that have arisen since the end of the
financial year which significantly affected, or may significantly affect, the operations of the Company, the
results of those operations, or the state of the Company in subsequent financial years.
13. SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS
Other than as disclosed in the financial statements, there were no significant changes in the state of affairs of
the Company during the financial year.
14. LIKELY DEVELOPMENTS AND EXPECTED RESULTS
Should any likely developments of the Company eventuate, this information will be made available to the
market in accordance with its continuous disclosure obligations under the ASX Listing Rules.
19
As atAs at30/06/202030/06/2019$ $ Cash and cash equivalents (a)5,040,4867,636,601Net assets / Total equity10,888,50515,664,546Contributed equity (b)47,924,60648,044,606Accumulated losses(44,526,846)(39,196,317)20202019201820172016Quoted price of ordinary shares at year end (cents) 2.20 1.00 4.80 6.00 7.20 Quoted price of options at year end (cents) - ----Loss per share (cents)0.480.900.880.880.54Dividends paid - ----
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
➢ OUTLOOK AND BUSINESS STRATEGY
Clinical Development Program
(i)
Following the successful results from XanaHES, and the pleasing data from the Target Occupancy and other
Xanamem studies informing on the optimum dosing and patient populations for the future trials, Actinogen
plans to initiate Phase II studies with Xanamem™ across a number of indications, recognising the current
Covid-19 related restrictions to trial patient access. In the interim, the Company continues to progress
detailed analyses on the substantial Xanamem dataset and advancing future trial planning activities, whilst
also continuing discussions with potential key strategic parties, submitting and progressing grant
applications, and continuing other ongoing business development activities. This work will help to ensure
that Actinogen is well-placed to undertake a range of new and carefully planned studies once the current
Covid-related restrictions are lifted.
As a priority, Actinogen is planning a clinical trial to evaluate Xanamem in the early stages of Alzheimer’s
disease - a condition known as Mild Cognitive Impairment (MCI). This MCI study elegantly links the positive
and compelling XanaHES results – where the Company demonstrated that Xanamem 20mg once daily
enhanced cognition in healthy older study participants – to an Alzheimer’s disease patient population.
Alzheimer’s disease is a serious and debilitating disease, representing a significant unmet medical need with
limited treatment options currently available. It also represents an attractive commercial opportunity, with
the target peak annual sales for Xanamem estimated at ~US$13.7bn, and significant upside potential for
earlier intervention.
Plans for Actinogen’s future trials also include cognitive impairment associated with schizophrenia and
diabetes, and the Company continues to assess new opportunities as they arise. This broadening portfolio
highlights the novel mechanism of action of our lead drug, and the breadth of treatment and development
opportunities available for Actinogen to explore with Xanamem.
Current active trials include the Phase I Target Occupancy study and several pre-clinical toxicology studies.
The Target Occupancy study has been delayed due to Covid-19 restrictions in Melbourne, with enrolment
of new patients is on hold. However, most patients have already been enrolled, allowing detailed data
analyses to be undertaken and to inform Actinogen’s further clinical development of Xanamem. Actinogen
expects the final four patients to be enrolled into the study as soon as possible after the Covid-19 restrictions
are lifted. The preclinical toxicology studies have recommenced following minor restrictions, and Actinogen
is confident that the positive data being generated with these studies will greatly aid the ongoing clinical
development of Xanamem by informing study design of the MCI study.
Continuing to Raise Awareness
(ii)
Following Actinogen’s successful participation in recent conferences, including the Advancement in
Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD) and BIO Digital, the Company remains
focused on driving awareness of Xanamem’s clinical development. Subsequent to the period, in July 2020,
Professor Craig Ritchie presented a poster on behalf of Actinogen at the Alzheimer’s Association
International Conference (AAIC). Additionally in July, Dr. Ketelbey was interviewed by Innovation
Intelligence International, with an article published highlighting the potential of a new Alzheimer’s disease
treatment, titled ‘Alzheimer’s treatment could be worth $10bn annually’, and presented at the Finance
News Network CEO Showcase, providing an update on Actinogen to shareholders and the investment
community.
The Company’s executives and business development team continue to participate (albeit virtually) in
selected international pharmaceutical, biotechnology, industry partnering conventions and investor
conferences to take every opportunity to showcase Xanamem’s significant potential, with the objective to
continue engaging with selected potential strategic partners and investors. The Company also continues
to progress manuscript writing of further Xanamem-related articles, following the recent completion of a
number of studies, with the expectation of publications being submitted and accepted by several journals
in CY20.
20
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
➢ REMUNERATION REPORT (AUDITED)
The information contained in the Remuneration Report has been audited, as required by Section 308(3C) of
the Corporations Act 2001. The Remuneration Report is set out under the following main headings:
1.
2.
3.
4.
5.
6.
7.
8.
9.
Introduction
Remuneration governance
Executive remuneration arrangements
A. Remuneration principles and strategy
B. Approach to setting remuneration
C. Details of incentive plans
Executive remuneration outcomes including link to performance
Executive contracts
Non-Executive Director fee arrangements
Disclosures relating to options
Disclosures relating to shares
Loans to Key Management Personnel (“KMP”) and their related parties
10.
Other transactions and balances with KMP and their related parties
1.
INTRODUCTION
The Remuneration Report details the remuneration arrangements for KMP who are defined as those having
authority and responsibility for planning, directing and controlling the major activities of the Company,
directly or indirectly, including any Director (whether executive or otherwise). The performance of the
Company depends upon the quality of its KMP. To prosper, the Company must attract, motivate and retain
appropriately skilled Directors and executives.
The Company’s broad remuneration policy is to ensure the remuneration package properly reflects the
person’s duties and responsibilities and that remuneration is competitive in attracting, retaining and
motivating people of the highest quality.
The people considered to be KMP during the financial year were:
There were no other changes to KMP after the reporting date and before the date that the financial report
was authorised for issue.
21
NamePositionAppointedResignedDr Geoffrey BrookeNon-Executive Chairman1/03/2017CurrentDr Bill KetelbeyManaging Director / Chief Executive Officer18/12/2014CurrentDr George MorstynNon-Executive Director1/12/2017CurrentMr Malcolm McComasNon-Executive Director4/04/2019Current
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
2.
REMUNERATION GOVERNANCE
The Board has not established a separate Remuneration Committee at this point in the Company’s
development nor has the Board engaged the services of a remuneration consultant to provide
recommendations when setting the remuneration received by Directors. Therefore, remuneration of
Directors is currently set by the Board of Directors, which is put to shareholders at the Annual General
Meeting (‘AGM’). At the AGM held on 25 November 2019, Actinogen Medical received 99% of votes in
favour of its Remuneration Report for the 2020 financial year. The Company did not receive any specific
feedback at the AGM or throughout the year on its remuneration practices.
It is considered that the size of the Board, along with the level of activity of the Company, renders having a
Remuneration Committee impractical and the full Board considers in detail all of the matters for which the
Directors are responsible. All matters of remuneration are performed in accordance with the Corporations
Act 2001 requirements, especially in respect of related party transactions. Refer to the Corporate
Governance Statement for further information.
3.
EXECUTIVE REMUNERATION ARRANGEMENTS
(A) Remuneration principles and strategy
The Company aims to reward executives with a level and mix of remuneration commensurate with their
position and responsibilities within the Company and aligned with market practice. Executive remuneration
must be:
• aligned with the Company’s vision, values and overall business objectives, and
• must be designed to motivate management to pursue the Company’s long-term growth and
success.
The nature and amount of remuneration of executives is assessed on a periodic basis by the Board (in the
absence of a Remuneration Committee) for their approval, with the overall objective of ensuring maximum
stakeholder benefit from the retention of high performing executives. The main objectives sought when
reviewing executive remuneration is that the Company has:
Executives who will create value for shareholders,
• coherent remuneration policies and practices to attract and retain executives,
•
• competitive remuneration offered benchmarked against the external market, and
•
fair and responsible rewards to executives having regard to the performance of the Company, the
performance of the executives and the general pay environment.
(B) Approach to setting remuneration
The Company aims to reward executives with a level and mix of remuneration appropriate to their position
and responsibilities, while being market competitive. The Company’s remuneration structure for executives
can include a mix of fixed remuneration, short term incentives and long-term incentives as outlined below.
Fixed remuneration component:
Fixed remuneration is represented by total employment cost and comprises base salary, statutory
superannuation contributions (where applicable) and other benefits. It is paid by the Company to
compensate fully for all requirements of the executive’s employment with reference to the market and the
individual’s role and experience. It is subject to annual review considering market data and the
performance of the Company and individual. The Company benchmarks the fixed component against
appropriate market comparisons with the comparator group criteria being market capitalisation.
Short-Term Incentive component:
The short-term incentive component is in the form of a cash bonus to executives of the Company (bonuses
are also applicable to selected employees). Payment of the cash bonus is entirely discretionary and rewards
the KMP for their contribution to achievement of business goals. The business goals are determined annually
by the Board and are linked to the strategic and operational plans of the Company, including budgets
agreed for each financial year.
22
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
A specific short-term incentive component is also provided for within the Managing Director’s remuneration
package. Currently this includes a performance condition whereby at the annual review of the Managing
Director’s salary, one of the factors to be considered by the Board when granting an increase will be the
Company’s market capitalisation against appropriate ASX benchmarks with an aim for 50th percentile pay
on ASX market capitalisation. The Managing Director and the remainder of the Board will agree benchmarks
for each year of the term.
Long Term Incentive component:
The long-term incentive component is in the form of Employee Options, Director Options and LTI Rights. The
Board is of the opinion that the shares and options currently on issue provide a sufficient long-term incentive
to align the goals of the KMP with those of the shareholders to maximise shareholder wealth. The Board will
continue to monitor this policy to ensure that it is appropriate for the Company in future years.
(C) Details of incentive plans
During the financial year ended 30 June 2020, the Board of Directors had in place various Short-term
Incentives and Long-term Incentives which are outlined below.
(a) Short Term Incentives (‘STIs’)
STIs are set each calendar year, with any unmet milestones expiring at the end of each calendar year
ending 31 December. During the financial years ended 30 June 2020 and 30 June 2019, the Board of
Directors put in place various STIs, and when achieved, a cash bonus was paid out to the following KMPs:
➢ Dr Ketelbey – Managing Director and Chief Executive Officer
An STI was put in place for the achievement of a number of various short-term performance conditions
relating to clinical development, capital raisings, and business development being met during the 2019
calendar year including XanADu analysis, patient enrolments, studies, planning, regulatory, budgeting,
data read-out, executed confidentiality agreements with potential partners, and drug development and
regulatory plan. Dr Ketelbey achieved a number of these milestones and was paid a $63,200 bonus in
January 2020.
(b) Long Term Incentives (‘LTIs’)
The LTIs currently in place are in the form of Employee Options and Director Options, they are summarised
below:
(i)
Employee Options
Directors are not eligible to receive Employee Options under the Employee Option Plan currently in place
with the Company. Furthermore, no employees of the Company were deemed to be KMP during the
financial years ended 30 June 2020 and 30 June 2019.
23
QuantityType of LTI2,100,000 Employee Options (A) (Tranche 1)417,188 Employee Options (B) (Tranche 2)1,042,110 Employee Options (C) (Tranche 3)5,783,333 Employee Options (E) (Tranche 4)1,500,000 Director Options (D)18,100,000 Director Options (F)5,000,000 Director Options (G)3,000,000 Director Options (H)36,942,631 Total number of options issued as LTIs
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
(ii) Director Options
There were no Director Options issued to current Directors during the current financial year ended 30 June
2020. In prior years, Directors Options were issued to current Directors of the Company, the specific details
are outlined in the section below. However, in all instances the general terms of each option issue are as
follows:
•
•
•
Entitlement: Each Option gives the holder (Option holder) the right to subscribe for one fully paid
ordinary share in the Company (Share) upon exercise of the Option.
Issue Price of Options: Options are issued for no consideration.
Valuation Methodology: Due to the vesting conditions attached to all Director Options issued, they
have been independently valued using a Black-Scholes methodology, whereby the total share-based
payment is expensed over the vesting period. Refer to Note 20: Share-based Payments for further
information.
• Other terms: The rights, restrictions and obligations which apply to Options, including in relation to
vesting, disposal and forfeiture, are pursuant to the terms of each Director’s engagement with the
Company, and the option offer letters accepted and signed by the Director at the time of the offer.
➢ Dr Geoffrey Brooke – Non-Executive Chairman:
During previous financial years, 4,900,000 Director Options (F) and 5,000,000 Director Options (G) were
granted to Dr Brooke on 28 November 2018 and on 24 March 2017, respectively.
The key terms of these two offers are outlined below:
Vesting Conditions:
• Director Options (F): 4,900,000 options to vest quarterly over a period of three years from the date of
grant and is subject to continuous service to the Company by Dr Brooke as Non-Executive Chairman
during the period from the date of grant up to and including the applicable vesting dates.
• Director Options (G): 2,000,000 options to vest one year after the date of grant, 1,500,000 options to vest
two years after the date of grant, and 1,500,000 options to vest three years after the date of grant. These
options have fully vested as at 30 June 2020.
➢ Dr Bill Ketelbey – Managing Director and Chief Executive Officer:
During the prior financial year, 11,700,000 Director Options (F) were granted to Dr Ketelbey on 28 November
2018. The key terms of the offer are outlined below:
24
Director Options (F)Director Options (G)Grant Date28/11/201824/03/2017Quantity4,900,0005,000,000Exercise Price$0.085$0.10Expiry Date27/11/202324/03/2025Director Options (F)Grant Date28/11/2018Quantity11,700,000Exercise Price$0.085Expiry Date27/11/2023
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
Vesting Conditions:
• Director Options (F): 11,700,000 options to vest quarterly over a period of three years from the date of
grant and is subject to continuous service to the Company by Dr Ketelbey as Managing Director during
the period from the date of grant up to and including the applicable vesting dates.
➢ Dr George Morstyn – Non-Executive Director:
During previous financial years, 1,500,000 Director Options (F) and 1,500,000 Director Options (D) were
granted to Dr Morstyn on 28 November 2018 and on 18 January 2018, respectively.
The key terms of these offers are outlined below:
Vesting Conditions:
• Director Options (F): 1,500,000 options to vest quarterly over a period of three years from the date of
grant and is subject to continuous service to the Company by Dr Morstyn as Non-Executive Director
during the period from the date of grant up to and including the applicable vesting dates.
• Director Options (D): 700,000 options to vest one year after the date of grant, 400,000 options to vest two
years after the date of grant, and 400,000 options to vest three years after the date of grant.
In each case, subject to continuous service to the Company by Dr Morstyn as Non-Executive Director. While
the terms of Dr Morstyn’s engagement state that the vesting periods commence from date of grant of the
Options, the intention when granting the options, was that the vesting period would commence from date
of appointment as a Non-Executive Director, which was 1 December 2017.
➢ Mr Malcolm McComas – Non-Executive Director:
During the prior financial year 3,000,000 Director Options (H) were granted to Mr McComas on 4 April 2019.
The key terms of the offer are outlined below:
Vesting Conditions:
• Director Options (H): 3,000,000 options to vest quarterly over a period of three years from the date of
grant and is subject to continuous service to the Company by Mr McComas as Non-Executive Director
during the period from the date of grant up to and including the applicable vesting dates.
25
Director Options (F)Director Options (D)Grant Date28/11/201818/01/2018Quantity1,500,0001,500,000Exercise Price$0.085$0.10Expiry Date27/11/20231/12/2022Director Options (H)Grant Date4/04/2019Quantity3,000,000Exercise Price$0.100Expiry Date4/04/2024
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
(iii) LTI Rights
At the beginning of the year the total loan value of LTI Rights (“Loan shares”) outstanding was $480,000
which related to Dr Ketelbey’s Class H, I and J LTI Rights.
LTI Rights have historically been accounted for as “in-substance options” under Australian Accounting
Standards, consequently, no loan amount is recognised in the financial statements on this basis. These LTI
Rights were issued with performance conditions attached, consisting of a number of Key Performance
Indicators (KPI’s) covering both financial and non-financial measures of performance. Typically included
were measures such as contribution to research and development success, share price appreciation and
tenure.
During the year, Dr Ketelbey repaid $360,000 attached to 6,000,000 Class H and 3,000,000 Class J LTI Rights.
The remaining 3,000,000 Class I LTI Right had vesting conditions attached to them that went unmet.
Subsequently, the Company decided to buy-back and cancel the 3,000,000 shares and release Dr Ketelbey
from the obligation to repay the remaining $120,000 share loan advance attached to them.
Refer to the table below setting out the vesting conditions attached to the LTI Rights.
(i) During the year, the 3,000,000 Class I Rights lapsed due to the vesting conditions attached them being unmet despite
the share-based payment expense against these Rights being fully expensed based on the expected vesting date
at that time.
In prior years, the following LTI Rights vested or lapsed:
(ii) On 18 December 2017, the vesting condition on 6,000,000 Class H Rights issued to Dr Ketelbey was met.
(iii) On 31 October 2018, the vesting condition on 3,000,000 Class J Rights issued to Dr Ketelbey was met.
As at 30 June 2020, there were no LTI Rights (“Loan shares”) on issue.
26
RecipientClassQuantity of LTI rights Exercise Price Loan amount attached to LTI Rights as at 1 July 2019Quantity of LTI Rights converted during the year Quantity of LTI Rights lapsed during the year Loan amount paidQuantity of LTI Rights held as at 30 June 2020Bill KetelbeyClass H6,000,000 0.04$ 240,000$ (6,000,000) - 240,000$ - Bill KetelbeyClass I3,000,000 0.04$ 120,000$ - (3,000,000) - - Bill KetelbeyClass J3,000,000 0.04$ 120,000$ (3,000,000) - 120,000$ - 12,000,000 480,000$ (9,000,000) (3,000,000) 360,000$ - Quantity of LTI RightsClassVesting DateVesting ConditionVested, unvested or lapsedRef.6,000,000 Class H15/12/2017Three years from commencement of employment.Vestediii3,000,000 Class I30/06/2015Upon Share trading on the ASX at 150% of the share price on the date of commencement of employment for 10 consecutive trading days.Lapsedi3,000,000 Class J30/06/2017Upon recruitment of Phase II Xanamen Study.Vestediii
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
4.
EXCUTIVE REMUNERATION OUTCOMES INCLUDING LINK TO PERFORMANCE
During the financial years ended 30 June 2020 and 30 June 2019 the KMP’s received either or all of the
following benefits:
Short-term benefits: cash salary, cash fees and cash bonuses
Post-employment benefits
•
•
• Other long-term benefits
•
Share-based payments
All remuneration paid to Directors and the other KMP is valued at the cost to the Company and expensed.
Table 1 - Remuneration of KMP for the year ended 30 June 2020:
(a) The total Non-Executive Director Fees including superannuation (excluding Dr Ketelbey) during the year totalled $224,560.
(b) During the year, Dr Ketelbey’s contract of employment had a total employment cost basis (inclusive of superannuation
guarantee) of $350,000 that increased to $367,500 (with effect from 1 January 2020) with entitlement to four weeks annual
leave.
Table 2 - Remuneration of KMP for the year ended 30 June 2019:
(a) The total Non-Executive Director fees including superannuation (excluding Dr Ketelbey) during the year totalled $195,000.
(b) During the year, Jason Loveridge resigned as Non-Executive Director on 28 November 2018.
(c) During the year, Malcom McComas was appointed as Non-Executive Director on 4 April 2019.
27
Year ended 30/6/2020Post-employmentLong-term benefitsCash, salary and feesCash bonusSuper-annuationAccrued leave benefits OptionsSharesDirectors (a)$$$$$$$ %Geoffrey Brooke 93,607 - 8,893 - 47,996 - 150,496 32%Bill Ketelbey (b) 311,087 63,200 24,202 26,660 55,380 - 480,529 12%George Morstyn 61,500 - - - 9,912 - 71,412 14%Malcolm McComas 61,500 - - - 14,132 - 75,632 19%Total Directors 527,694 63,200 33,095 26,660 127,420 - 778,069 Short-term benefitsShare-based paymentsValue of SBP as a % of total remunerationTotalYear ended 30/6/2019Post-employmentLong-term benefitsCash, salary and feesCash bonusSuper-annuationAccrued leave benefits LTI Rights / OptionsSharesDirectors (a)$$$$$$$ %Geoffrey Brooke 91,324 - 8,676 - 60,016 - 160,016 38%Bill Ketelbey 318,081 80,000 20,531 11,388 27,690 - 457,690 6%Jason Loveridge (b) 20,000 - - - - - 20,000 - George Morstyn 60,000 - - - 11,658 - 71,658 16%Malcolm McComas (c) 15,000 - - - 3,533 - 18,533 19%Total Directors 504,405 80,000 29,207 11,388 102,897 - 727,897 Short-term benefitsShare-based paymentsValue of SBP as a % of total remunerationTotal
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
5.
EXECUTIVE CONTRACTS
During the financial year the following executive was remunerated for his role and was subject to the
following contractual arrangement:
•
Dr Bill Ketelbey – Managing Director and Chief Executive Officer
- Commencement of employment: 18 December 2014.
-
Remuneration package: A total employment cost basis (inclusive of superannuation guarantee) of
$350,000 that increased to $367,500 (with effect from 1 January 2020) with four weeks annual leave
entitlement.
Included within the remuneration package is an STI scheme which is put in place by the Board of
Directors for the achievement of a number of various short-term performance conditions being met.
For further information on the STI’s refer to Section 3(C) of the Remuneration Report.
Term: The appointment of the employee will continue on an ongoing basis unless terminated earlier
in accordance with termination provisions.
Termination: The Company or the individual may terminate the contract by giving three months’
written notice. In the event of breach or criminal activity, termination is effective immediately
without payment other than the fee accrued to the date of termination.
6.
NON-EXECUTIVE DIRECTOR FEE ARRANGEMENTS
Non-Executive Directors are remunerated by way of fees, in the form of cash, non-cash benefits and
superannuation contributions and do not normally participate in schemes designed for the remuneration
of executives. As noted above, fees for Non-Executive Directors are generally not directly linked to the
performance of the Company, however, to align Directors’ interests with shareholder interests, the Directors
are encouraged to hold shares in the Company.
The maximum aggregate remuneration approved by shareholders for Non-Executive Directors, at an
Annual General Meeting held on 12 November 2015, is $500,000 per annum. The Directors set the individual
Non-Executive Directors fees within the limit approved by shareholders. Total fees, including superannuation,
paid to Non-Executive Directors during the year were $224,560.
During the financial year the following Non-Executive Directors were remunerated for their respective roles
and were subject to the following contractual arrangements:
•
Dr Geoffrey Brooke – Non-Executive Chairman
- Date of Appointment: 1 March 2017.
-
Remuneration package set at $100,000 per annum (plus GST, inclusive of statutory superannuation)
that increased to $105,000 per annum with effect from 1 January 2020. Subject to annual review.
Term: Dr Brooke’s appointment is subject to retirement by rotation under the Company’s
Constitution.
Termination: The other members of the Board may request that the officer resign with immediate
effect in the event that the Board deems the individual’s performance is unsatisfactory, or the
Company’s shareholders may resolve to seek the officer’s removal by members’ resolution.
Alternatively, the individual may resign from the Board.
-
-
-
-
-
28
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
•
Dr George Morstyn – Non-Executive Director
- Date of Appointment: 1 December 2017.
-
Remuneration package set at $60,000 per annum (plus GST and exclusive of superannuation) that
increased to $63,000 per annum with effect from 1 January 2020. Subject to annual review.
Term: Dr Morstyn’s appointment is subject to retirement by rotation under the Company’s
Constitution.
Termination: The other members of the Board may request that the officer resign with immediate
effect in the event that the Board deems the individual’s performance is unsatisfactory, or the
Company’s shareholders may resolve to seek the officer’s removal by members’ resolution.
Alternatively, the individual may resign from the Board.
• Mr. Malcolm McComas – Non-Executive Director
- Date of Appointment: 4 April 2019.
-
Remuneration package set at $60,000 per annum (plus GST and exclusive of superannuation) that
increased to $63,000 per annum with effect from 1 January 2020. Subject to annual review.
Term: Dr McComas’ appointment is subject to retirement by rotation under the Company’s
Constitution.
Termination: The other members of the Board may request that the officer resign with immediate
effect in the event that the Board deems the individual’s performance is unsatisfactory, or the
Company’s shareholders may resolve to seek the officer’s removal by members’ resolution.
Alternatively, the individual may resign from the Board.
-
-
-
-
29
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
7.
(i)
DISCLOSURES RELATING TO OPTIONS
Option holding of KMP
At the date of this Report, the unissued ordinary shares of Actinogen Medical under option carry no dividend
or voting rights. When exercisable, each option is convertible into one fully paid ordinary share of the
Company.
Option holdings of KMP as at 30 June 2020:
(a) Refer to Section 3(C)(b)(iii) within the Remuneration Report for further information on LTI Rights.
(b) Mr McComas 3,000,000 Director Options were granted on 4 April 2019 and vest every quarter subsequent to grant
date. As at 30 June 2020, only 4 quarters have vested with the fifth quarter vesting subsequent to year end, on 4
July 2020. Therefore, for quantitative purposes, 1,000,000 of the 3,000,000 options have vested as at 30 June 2020.
However, when calculating the share-based payment expense attached to these options, the expense has been
prorated based on 5 quarters vesting (representative of 1,250,000 options). Refer to Section 7(ii) for further
information.
30
Director / Class of OptionsBalance at beginning of year 1/7/2019Granted as remunerationNet change other (a)Balance at end of year 30/6/2020Vested at 30/6/2020(b)Not vested at 30/6/2020Geoffrey BrookeDirector Options (G)5,000,000 - - 5,000,000 5,000,000 - Director Options (F)4,900,000 - - 4,900,000 2,450,000 2,450,000 9,900,000 - - 9,900,000 7,450,000 2,450,000 Bill KetelbeyClass H LTI Rights6,000,000 - (6,000,000) - - - Class I LTI Rights3,000,000 - (3,000,000) - - - Class J LTI Rights3,000,000 - (3,000,000) - - - Director Options (F)11,700,000 - - 11,700,000 5,850,000 5,850,000 23,700,000 - (12,000,000) 11,700,000 5,850,000 5,850,000 George MorstynDirector Options (D)1,500,000 - - 1,500,000 1,100,000 400,000 Director Options (F)1,500,000 - - 1,500,000 750,000 750,000 3,000,000 - - 3,000,000 1,850,000 1,150,000 Malcolm McComasDirector Options (H)3,000,000 - - 3,000,000 1,000,000 2,000,000 3,000,000 - - 3,000,000 1,000,000 2,000,000 Total Directors39,600,000 - (12,000,000) 27,600,000 16,150,000 11,450,000
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
Option holdings of KMP as at 30 June 2019:
(c) Class I LTI Rights: As at 30 June 2019, these LTI Rights remain unvested as the vesting condition has not yet been
met despite the share-based payment expense against these LTI Rights being fully expensed in prior years
based on the expected vesting date at that time.
(d) Director Options (H): Mr McComas was appointed as Non-Executive Director on 4 April 2019, and he was issued
3,000,000 Director Options as part of his appointment. The 3,000,000 Director Options vest every quarter
subsequent to grant date. As at 30 June 2019, no quarters had passed as the first quarter vesting date occurred
subsequent to year end, on 4 July 2019. Therefore, for quantitative purposes, 3,000,000 options remain unvested
as at 30 June 2019.
However, when calculating the share-based payment expense attached to these options, the expense has
been prorated based on 1 quarter vesting (representative of 250,000 options).
(e) Dr Loveridge resigned as Non-Executive Director on 28 November 2018.
31
Director / Class of OptionsBalance at beginning of year 1/7/2018Granted as remunerationNet change other(e)Balance at end of year 30/6/2019Vested at 30/6/2019(d)Not vested at 30/6/2019(c)Geoffrey BrookeDirector Options (G)5,000,000 - - 5,000,000 3,500,000 1,500,000 Director Options (F)- 4,900,000 - 4,900,000 816,667 4,083,333 5,000,000 4,900,000 - 9,900,000 4,316,667 5,583,333 Bill KetelbeyClass H LTI Rights6,000,000 - - 6,000,000 6,000,000 - Class I LTI Rights3,000,000 - - 3,000,000 - 3,000,000 Class J LTI Rights3,000,000 - - 3,000,000 3,000,000 - Director Options (F)- 11,700,000 - 11,700,000 1,950,000 9,750,000 12,000,000 11,700,000 - 23,700,000 10,950,000 12,750,000 George MorstynDirector Options (D)1,500,000 - - 1,500,000 700,000 800,000 Director Options (F)- 1,500,000 - 1,500,000 250,000 1,250,000 1,500,000 1,500,000 - 3,000,000 950,000 2,050,000 Malcolm McComasDirector Options (H)- 3,000,000 - 3,000,000 - 3,000,000 - 3,000,000 - 3,000,000 - 3,000,000 Jason LoveridgeClass A LTI Rights3,000,000 - (3,000,000) - - - Class B LTI Rights3,000,000 - (3,000,000) - - - 6,000,000 - (6,000,000) - - - Total Directors24,500,000 21,100,000 (6,000,000) 39,600,000 16,216,667 23,383,333
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
(ii)
Value of options awarded, vested and lapsed during the financial year
(a) Refer to Note 7(i)(b) for further information regarding Mr. McComas options.
32
Directors / Class of option issuedTotal share-based payment valuationValue vested during the yearTotal share-based payments expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Total share-based payments expensed as at 30 June 2020Value to be recognised in future yearsRemuneration consisting of option for the year (%)G. BrookeDirector Options (G)98,114$ -$ 98,114$ -$ -$ 98,114$ -$ 0%Director Options (G)73,586$ -$ 73,586$ -$ -$ 73,586$ -$ 0%Director Options (G)73,586$ -$ 48,783$ 24,803$ -$ 73,586$ -$ 16%Director Options (F)69,580$ 23,193$ 11,597$ 23,193$ -$ 34,790$ 34,790$ 15%B. KetelbeyClass H LTI Rights218,886$ -$ 218,886$ -$ -$ 218,886$ -$ 0%Class I LTI Rights109,443$ -$ 109,443$ -$ -$ 109,443$ -$ 0%Class J LTI Rights109,443$ -$ 109,443$ -$ -$ 109,443$ -$ 0%Director Options (F)166,140$ 55,380$ 27,690$ 55,380$ -$ 83,070$ 83,070$ 12%G. MorstynDirector Options (D)9,030$ -$ 9,030$ -$ -$ 9,030$ -$ 0%Director Options (D)5,160$ -$ 4,071$ 1,089$ -$ 5,160$ -$ 2%Director Options (D)5,160$ -$ 2,712$ 1,723$ -$ 4,435$ 725$ 2%Director Options (F)21,300$ 7,100$ 3,550$ 7,100$ -$ 10,650$ 10,650$ 10%M. McComas (a)Director Options (H)42,396$ 14,132$ 3,533$ 14,132$ -$ 17,665$ 24,731$ 19%Total Directors1,001,824$ 99,805$ 720,438$ 127,420$ -$ 847,858$ 153,966$
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
(iii)
Number of options awarded, vested and lapsed during the financial year
(a) Options vest quarterly over a period of three years from the date of grant and is subject to continuous service to the Company by the Director during
the period from the date of grant up to and including the applicable vesting dates.
33
Directors / Class of option issuedGrant DateFair value per option at grant dateFinacial YearVesting dateExercise priceExpiry dateQuantity as at 1 July 2019Quantity converted / lapsed during the year Quantity as at 30 June 2020Quantity vested during the yearG. BrookeDirector Options (G)24/03/20170.049$ 201724/03/20180.10$ 24/03/20252,000,000 - 2,000,000 - Director Options (G)24/03/20170.049$ 201724/03/20190.10$ 24/03/20251,500,000 - 1,500,000 - Director Options (G)24/03/20170.049$ 201724/08/20200.10$ 24/03/20251,500,000 - 1,500,000 1,500,000 Director Options (F)28/11/20180.014$ 2019Refer to (a)0.09$ 27/11/20234,900,000 - 4,900,000 1,633,333 B. KetelbeyClass H LTI Rights15/12/20140.036$ 201518/12/20170.04$ 15/12/20196,000,000 (6,000,000) - - Class I LTI Rights15/12/20140.036$ 201530/06/20150.04$ 15/12/20193,000,000 (3,000,000) - - Class J LTI Rights15/12/20140.036$ 201530/06/20170.04$ 15/12/20193,000,000 (3,000,000) - - Director Options (F)28/11/20180.014$ 2019Refer to (a)0.09$ 27/11/202311,700,000 - 11,700,000 3,900,000 G. MorstynDirector Options (D)18/01/20180.013$ 20181/12/20180.10$ 1/12/2022700,000 - 700,000 - Director Options (D)18/01/20180.013$ 20181/12/20190.10$ 1/12/2022400,000 - 400,000 - Director Options (D)18/01/20180.013$ 20181/12/20200.10$ 1/12/2022400,000 - 400,000 - Director Options (F)28/11/20180.014$ 2019Refer to (a)0.09$ 27/11/20231,500,000 - 1,500,000 500,000 M. McComasDirector Options (H)4/04/20190.014$ 2019Refer to (a)0.10$ 4/04/20243,000,000 - 3,000,000 1,000,000 Total Directors39,600,000 (12,000,000) 27,600,000 8,533,333
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
8.
DISCLOSURES RELATING TO SHARES
There were no shares issued as compensation to KMP during the financial year ended 30 June 2020.
The shareholding of KMP as at 30 June 2020 was as follows:
(a) During the year, Dr Ketelbey repaid $360,000 attached to 9,000,000 LTI Rights (“Loan shares”) that prior to
repayment represented ordinary shares that were accounted for as “in-substance” options. However, since
repayment, these represent fully paid ordinary shares. Refer to Section 3(C)(b)(iii) within the Remuneration
Report for information on LTI Rights.
There were no shares issued as compensation to KMP during the financial year ended 30 June 2019.
The shareholding of KMP as at 30 June 2019 was as follows:
(a) Movement relates to shares purchased by Dr Brooke and Dr Ketelbey pursuant to the Share Purchase Plan
issued 13/7/2018, shares purchased by Mr McComas on-market prior to his appointment as a director, and Dr
Loveridge’s resignation on 28 November 2019.
9.
LOANS MADE TO KEY MANAGEMENT PERSONNEL AND THEIR RELATED PARTIES
No loans were made to any KMP or any of their related entities during the reporting period. In a prior
year, limited recourse interest free loans were provided to Dr Ketelbey in the form of LTI Rights. These LTI
Rights were not accounted for as loans, rather they were accounted for as “in-substance options”.
During the year, Dr Ketelbey repaid the loans outstanding of $360,000 which related to the Class H and
J LTI Rights (Class I LTI Rights lapsed). As at 30 June 2020, there are no loans held with any KMP or any
of their related entities.
10.
OTHER TRANSACTIONS WITH KEY MANAGEMNET PRESONNEL AND THEIR RELATED PARTIES
There were no other transactions with any Director of KMP or any of their related entities during the year.
END OF AUDITED REMUNERATION REPORT
34
DirectorsBalance at beginning of year 1/7/2019Granted as remunerationOn exercise of optionsNet change other (a)Balance at end of year 30/6/2020Geoffrey Brooke1,325,000 - - - 1,325,000 Bill Ketelbey953,803 - - 9,000,000 9,953,803 George Morstyn200,000 - - - 200,000 Malcolm McComas500,000 - - - 500,000 Total Directors2,978,803 - - 9,000,000 11,978,803 DirectorsBalance at beginning of year 1/7/2018Granted as remunerationOn exercise of optionsNet change other (a)Balance at end of year 30/6/2019Geoffrey Brooke1,025,000 - - 300,000 1,325,000 Bill Ketelbey (b)353,803 - - 600,000 953,803 Jason Loveridge21,875,078 - - (21,875,078) - George Morstyn200,000 - - - 200,000 Malcolm McComas- - - 500,000 500,000 Total Directors23,453,881 - - (20,475,078) 2,978,803
ACTINOGEN MEDICAL LIMITED
D I R E C T O R S ’ R E P O R T
_____________________________________________________________
15.
INDEMNIFICATION OF AUDITORS
To the extent permitted by law, the Company has agreed to indemnify its auditors, Ernst & Young, as part
of the terms of its audit engagement agreement against claims by third parties arising from the audit (for
an unspecified amount). No payment has been made to indemnify Ernst & Young during or since the
financial year.
16.
INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS
During the financial year, Actinogen Medical paid a base premium of $38,222 to insure the Directors and
officers of the Company. The liabilities insured are legal costs that may be incurred in defending civil or
criminal proceedings that may be brought against the officers in their capacity as officers in the
Company, and any other payments arising from liabilities incurred by the officers in connection with such
proceedings.
This does not include such liabilities that arise from conduct involving a wilful breach of duty by the officers
or the improper use by the officers of their position or of information to gain advantage for themselves or
someone else or to cause detriment to the Company. It is not possible to apportion the premium between
amounts relating to the insurance against legal costs and those relating to other liabilities.
17. PROCEEDINGS ON BEHALF OF THE COMPANY
No person has applied for leave of Court, under section 237 of the Corporations Act 2001, to bring
proceedings on behalf of the Company or intervene in any proceedings to which the Company is party
for the purpose of taking responsibility on behalf of the Company for all or part of these proceedings. The
Company was not a party to any such proceedings during the year.
18. ENVIRONMENTAL REGULATIONS
The Company's operations are not subject to significant environmental regulation under the Australian
Commonwealth or State law.
19. NON-AUDIT SERVICES
$2,600 in non-audit services were paid to the external auditors and their associated entities during the
years ended 30 June 2020 and 30 June 2019.
20. AUDITOR’S INDEPENDENCE DECLARATION
The Auditor’s Independence Declaration as required under section 307C of the Corporations Act 2001
for the year ended 30 June 2020 forms a part of the Directors’ Report and can be found on page 36.
Signed in accordance with a resolution of the Board of Directors.
Dr Bill Ketelbey
Managing Director
Sydney, New South Wales
Wednesday, 26 August 2020
35
Ernst & Young
11 Mounts Bay Road
Perth WA 6000 Australia
GPO Box M939 Perth WA 6843
Tel: +61 8 9429 2222
Fax: +61 8 9429 2436
ey.com/au
Auditor’s independence declaration to the directors of Actinogen Medical
Limited
As lead auditor for the audit of the financial report of Actinogen Medical Limited for the financial year
ended 30 June 2020, I declare to the best of my knowledge and belief, there have been:
a) no contraventions of the auditor independence requirements of the Corporations Act 2001 in
relation to the audit; and
b) no contraventions of any applicable code of professional conduct in relation to the audit.
Ernst & Young
Pierre Dreyer
Partner
26 August 2020
A member firm of Ernst & Young Global Limited
Liability limited by a scheme approved under Professional Standards Legislation
PD:JG:ACW:008
ACTINOGEN MEDICAL LIMITED
S T A T E M E N T O F C O M P R E H E N S I V E I N C O M E
F o r t h e y e a r e n d e d 3 0 J u n e 2 0 2 0
__________________________________________________________________
The above Statement of Comprehensive Income should be read in conjunction with the accompanying Notes.
37
Full year endedFull year ended30/06/202030/06/2019Note$ $ Interest income 94,057 204,546 Other income 3,516,397 4,862,755 Total revenue & other income6 3,610,454 5,067,301 Research & development costs6 (5,537,170) (10,895,271)Employment costs (1,538,700) (1,658,438)Corporate & administration costs (480,265) (658,886)Business development & investor relations (748,545) (776,052)Finance costs (28,882) (7,987)Share-based payment expenses (194,488) (127,949)Amortisation expense11 (313,602) (353,500)Impairment loss11 - (476,900)Depreciation expense (right-of-use asset)2(w)(iv) (95,112) - Depreciation expense (office equipment)10 (4,219) - Total expenses (8,940,983) (14,954,983)Loss before income tax (5,330,529) (9,887,682)Income tax expense7 - - Loss for the Year(5,330,529)(9,887,682)Other comprehensive incomeItems that may be reclassified subsequently to profit and loss:Other comprehensive income - - Total comprehensive loss for the Year(5,330,529)(9,887,682)Loss per share for attributable to the ordinary equity holders of the CompanyBasic loss per share (cents)15(0.48)(0.90)Diluted loss per share (cents)15(0.48)(0.90)
ACTINOGEN MEDICAL LIMITED
S T A T E M E N T O F F I N A N C I A L P O S I T I O N
A s a t 3 0 J u n e 2 0 2 0
_________________________________________________________________
The above Statement of Financial Position should be read in conjunction with the accompanying Notes.
38
As atAs at30/06/202030/06/2019Note$ $CURRENT ASSETSCash and cash equivalents85,040,4867,636,601Other receivables93,123,4284,890,521TOTAL CURRENT ASSETS8,163,91412,527,122NON-CURRENT ASSETSProperty, plant and equipment10 18,541 - Intangible assets11 3,345,951 3,659,553 Other receivable - restricted cash 35,266 35,266 Right-of-use assets2(w)(iv) 372,501 - TOTAL NON-CURRENT ASSETS3,772,2593,694,819TOTAL ASSETS11,936,17316,221,941CURRENT LIABILITIESTrade and other payables12509,275433,575Provisions148,523 123,820 Lease liability2(w)(iv)86,018 - TOTAL CURRENT LIABILITIES743,816557,395NON-CURRENT LIABILITIESLease liability2(w)(iv)303,852 - TOTAL NON-CURRENT LIABILITIES303,852 - TOTAL LIABILITIES1,047,668557,395NET ASSETS 10,888,50515,664,546EQUITYContributed equity1347,924,60648,044,606Reserve shares13 - (480,000)Reserves147,490,745 7,296,257 Accumulated losses(44,526,846)(39,196,317)TOTAL EQUITY 10,888,50515,664,546
ACTINOGEN MEDICAL LIMITED
S T A T E M E N T O F C A S H F L O W S
F o r t h e y e a r e n d e d 3 0 J u n e 2 0 2 0
_________________________________________________________________
The above Statement of Cash Flows should be read in conjunction with the accompanying Notes.
39
Full year endedFull year ended30/06/202030/06/2019$ $CASH FLOWS FROM OPERATING ACTIVITIESInterest received94,057204,546Interest paid(28,882) (7,987)Payments to suppliers and employees(1,151,125) (1,300,665)Payments for research and development(7,227,705) (12,633,011)Government grants and rebate received 5,458,042 3,238,819Net cash outflow from operating activities8(2,855,613)(10,498,298)CASH FLOWS FROM INVESTING ACTIVITIESPurchase of property, plant and equipment10 (22,760) - NAB bank guarantee (restricted cash) for Sydney office premises. - 71,771 Net cash (outflow)/inflow from investing activities (22,760)71,771CASH FLOWS FROM FINANCING ACTIVITIESProceeds from issue of shares - 7,923,616 Transaction costs associated with issue of shares - (317,248)Proceeds received on repayment of LTI Rights 360,000 560,000 Principal repayment on leases (77,742) - Net cash inflow from financing activities 282,258 8,166,368 Net decrease in cash and cash equivalents(2,596,115)(2,260,159)Cash and cash equivalents at beginning of the year7,636,6019,896,760CASH AND CASH EQUIVALENTS AT END OF THE YEAR85,040,4867,636,601Note
ACTINOGEN MEDICAL LIMITED
S T A T E M E N T O F C H A N G E S I N E Q U I T Y
F o r t h e y e a r e n d e d 3 0 J u n e 2 0 2 0
_________________________________________________________________
The above Statement of Changes in Equity should be read in conjunction with the accompanying Notes.
40
Contributed EquityAccumulated LossesOption ReserveReserve SharesTotalFull year ended 30/6/2020$$$$$Balance as at 1/7/201948,044,606(39,196,317)7,296,257(480,000)15,664,546Loss for the year - (5,330,529) - - (5,330,529)Other comprehensive income - - - - Total comprehensive loss for the year - (5,330,529) - - (5,330,529)Transactions with equity holders in their capacity as equity holders:Repayment of LTI Rights - - - 360,000 360,000 Cancellation of LTI Rights upon cessation of employment (120,000) - - 120,000 - Share-based payments - - 194,488 - 194,488.00 Balance as at 30/6/202047,924,606(44,526,846)7,490,745 - 10,888,505Contributed EquityAccumulated LossesOption ReserveReserve SharesTotalFull year ended 30/6/2019$$$$$Balance as at 1/7/201840,438,238(29,308,635)7,168,308(1,040,000)17,257,911Loss for the year - (9,887,682) - - (9,887,682)Other comprehensive income - - - - - Total comprehensive loss for the year - (9,887,682) - - (9,887,682)Transactions with equity holders in their capacity as equity holders:Shares issued during the year 7,923,616 - - - 7,923,616 Capital raising costs (317,248) - - - (317,248)Repayment of LTI Rights upon cessation of employment - - - 560,000 560,000 Share-based payments - - 127,949 - 127,949 Balance as at 30/6/201948,044,606(39,196,317)7,296,257(480,000)15,664,546
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
1.
CORPORATE INFORMATION
The financial statements of Actinogen Medical Limited (‘Actinogen Medical’ or ‘the Company’) for the
year ended 30 June 2020 were authorised in accordance with a resolution of Directors on 26 August
2020.
Actinogen Medical is a for profit company limited by shares incorporated and domiciled in Australia
whose shares are publicly traded on the Australian Securities Exchange (‘ASX’). The nature of
operations and principal activities of the Company are described in the Directors’ Report.
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The principal accounting policies adopted in the preparation of these financial statements are set out
below. These policies have been consistently applied to all the years presented, unless otherwise stated
below. The financial statements of the Company are for the financial year ended 30 June 2020.
(a)
Basis of preparation
These general-purpose financial statements have been prepared in accordance with Australian
Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards
Board, and the Corporations Act 2001. The financial statements have been prepared on a going
concern basis. The financial statements are presented in Australian dollars.
(b) Going concern basis
This financial report has been prepared on the going concern basis which contemplates the continuity
of normal business activity and the realisation of assets and settlement of liabilities in the normal course
of business.
The Company has incurred a loss after tax for the year ended 30 June 2020 of $5,330,529 (30 June 2019:
$9,887,682) and experienced net cash outflows from operating activities of $2,885,613 (30 June 2019:
$10,498,298).
In arriving at this position, the Directors have had regard for the fact that based on the matters noted
below the Company has, or in the Directors’ opinion will have access to, sufficient cash to fund
administrative and other committed expenditure for a period of not less than 12 months from the date
of this Report.
In forming this view the Directors have taken into consideration the following:
•
•
•
The Company has $5,040,486 in cash and cash equivalents as at 30 June 2020. The Company is
listed on the ASX and therefore has access to the Australian equity capital markets. Accordingly,
the Directors consider that the Company maintains a reasonable expectation of being able to
raise funding from the market as and when required, although it cannot determine in advance
the terms upon which it may raise such funding.
Following the reported positive and robust efficacy and safety results from the XanaHES trial in
October 2019, the Company finalised a number of additional studies that together confirm the
mechanism of action and safety of Xanamem 20 mg daily, and give the Directors confidence in
the potential of Xanamem to initiate a series of Phase 2 studies expected to provide proof-of-
concept for Xanamem in a range of patient populations. This provides the Directors with
confidence as regards the Company’s prospects of generating positive cash flow in the future.
As the unprecedented global crisis resulting from the Covid-19 outbreak continues to evolve, the
Company is emerging with limited disruption through careful and proactive management and is
in a strong position to commence new clinical trials, once the limitations to patient access are
lifted. In response to the pandemic, in March 2020 the Company implemented non-R&D related
expense savings across the business, with $250,000 in savings made within FY2020 and greater than
$500,000 is expected to be saved over the calendar year 2020. The R&D budget is being retained
to ensure continued Xanamem development.
41
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
•
The Company will be submitting a claim for the Research and Development Tax Incentive in
respect of the 2020 tax year. The Company is satisfied that it meets the criteria to qualify for a cash
refund and is confident the expenditure to be claimed will satisfy the tests of eligibility. The amount
of eligible expenditure in the 2020 financial year is estimated to be $6,628,837, and if approved,
would lead to a cash refund of $2,883,544 which has been recognised in the current year financial
statements. Refer to Note 9: Trade and other receivables.
(c) Compliance with IFRS
The financial statements of the Company also comply with International Financial Reporting Standards
(IFRS) as issued by the International Accounting Standards Board (IASB).
(d)
Historical cost convention
These financial statements have been prepared under the historical cost convention, except for certain
financial assets which have been measured at fair value.
(e) Critical accounting estimates
The preparation of financial statements requires the use of certain critical accounting estimates. It also
requires management to exercise its judgement in the process of applying the Company’s accounting
policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions
and estimates are significant to the financial statements are disclosed in Note 4.
(f)
Plant & equipment
Each asset of plant and equipment is stated at cost, net of accumulated depreciation and impairment
losses, if any. Assets are depreciated from the date the asset is ready for use. Items of plant and
equipment are depreciated using the diminishing value method over their estimated useful lives to the
Company. The depreciation rates used for each class of asset for the current period are as follows:
Computer Equipment
•
• General Pool Assets >$1,000
25% to 66.67%
37%
An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying
amount is greater than its estimated recoverable amount. The recoverable amount is assessed on the
basis of expected net cash flows that will be received from the assets continual use or subsequent
disposal. The expected cash flows have been discounted to their present value in determining the
recoverable amount.
An asset is de-recognised upon disposal or when no future economic benefits are expected from its use
or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between
the net disposal proceeds and the carrying amount of the asset) is included in the Statement of
Comprehensive Income when the asset is de-recognised. The assets’ residual values, useful lives and
methods of depreciation are reviewed, and adjusted if appropriate, at each balance date.
(g)
Impairment of non-financial assets
At each reporting date, the Company reviews the carrying values of its assets to determine whether
there is any indication that those assets have been impaired. If such an indication exists, the recoverable
amount of the asset, being the higher of the asset’s fair value less costs of disposal and value in use, is
compared to the assets carrying value. Any excess of the assets carrying value over its recoverable
amount is expensed to the Statement of Comprehensive Income. Where it is not possible to estimate
the recoverable amount of an individual asset, the Company estimates the recoverable amount of the
cash-generating unit to which the asset belongs.
In assessing value in use, the estimated future cash flows are discounted to their present value using a
pre-tax discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset. In determining fair value less cost of disposal, recent market transactions are taken
into account. If no such transactions can be identified, an appropriate valuation model is used. These
calculations are corroborated by valuation multiples, quoted share prices for publicly traded
companies or other available fair value measures.
42
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
(h)
Intangible assets
Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible
assets acquired in a business combination is their fair value at the date of acquisition. Following initial
recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated
impairment losses. Internally generated intangibles, excluding capitalised development costs, are not
capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure
is incurred.
The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite
lives are amortised over the useful economic life and assessed for impairment whenever there is an
indication that the intangible asset may be impaired. The amortisation period and the amortisation
method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting
period. Changes in the expected useful life or the expected pattern of consumption of future economic
benefits embodied in the asset are considered to modify the amortisation period or method, as
appropriate, and are treated as changes in accounting estimates and adjusted on a prospective basis.
The amortisation expense on intangible assets with finite lives is recognised in the Statement of
Comprehensive Income.
Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually,
and when indicators of impairment exist, individually or at the cash-generating unit level. The
assessment of indefinite life is reviewed annually, or when indicators of impairment exist, to determine
whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to
finite is made on a prospective basis. Gains or losses arising from derecognition of an intangible asset
are measured as the difference between the net disposal proceeds and the carrying amount of the
asset and are recognised in the Statement of Comprehensive Income when the asset is derecognised.
(i) Research and development costs
Development expenditure on an individual project is recognised as an intangible asset when the
Company can demonstrate:
•
•
•
•
•
•
The technical feasibility of completing the intangible asset so that the asset will be available for
use or sale
Its intention to complete and its ability to use or sell the asset
How the asset will generate future economic benefits
The availability of resources to complete the asset
The ability to measure reliably the expenditure during development
The ability to use the intangible asset generated
Following initial recognition of the development expenditure as an asset, the asset is carried at cost less
any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins
when development is complete, and the asset is available for use. It is amortised over the period of
expected future benefit. During the period of development, the asset is tested for impairment annually.
The Company assessed whether the above criteria had been met for the financial year ended 30 June
2020. The Company did not meet this criterion and as a consequence all research and development
costs were expensed to profit and loss for the current year.
(ii)
Intellectual property
The Company’s intangible assets relate to intellectual property for upfront payments to purchase
patents and licenses. The patents and licenses have been granted for a period of 20 years by the
relevant government agency with the option of renewal at the end of this period. As a result, those
patents and licenses are amortised on a straight-line basis over the period of the patent patents and
license. The remaining life of the patents and licenses is 11 years. Refer to Note 11: Intangible Assets.
(i)
Government grants
Research and development tax rebates are treated as a government grant. Government grants are
recognised as income where there is reasonable assurance that the grant will be received, and all
attached conditions will be complied with. When the grant relates to an expense item, it is recognised
as income on a systematic basis over the periods that the costs, which it is intended to compensate,
are expensed.
43
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
(j)
Income tax
The charge for current income tax expense is based on the result for the year adjusted for any non-
assessable or disallowed items. It is calculated using the tax rates that have been enacted or are
substantially enacted by the end of the reporting period.
Deferred income tax is accounted for using the liability method on temporary differences arising
between the tax bases of assets and liabilities and their carrying amounts in the financial statements.
However, the deferred income tax from the initial recognition of an asset or liability, in a transaction
other than a business combination is not accounted for if it arises that at the time of the transaction,
and affects neither accounting or taxable profit or loss.
Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially
enacted by the end of the reporting period and are expected to apply when the asset is realised, or
liability is settled. Deferred tax assets are recognised for deductible temporary differences and unused
tax losses only if it is probable that future taxable amounts will be available to utilise those temporary
differences and losses.
Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax
assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current
tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and
intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Current
and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in
other comprehensive income or directly in equity. In this case, the tax is also recognised in other
comprehensive income or directly in equity, respectively.
(k)
Employee benefits
Provision is made for the Company’s liability for employee benefits arising from services rendered by
employees to balance date. Employee benefits that are expected to be settled within one year have
been measured at the amounts expected to be paid when the liability is settled, plus related on-costs.
Employee benefits payable later than one year have been measured at the present value of the
estimated future cash outflows to be made for those benefits discounted using the interest rate on high
quality corporate bonds with terms to maturity approximating the terms of the liability.
(l)
Share-based payments
The Company provides benefits to employees (including Directors) and consultants of the Company in
the form of share-based payment transactions, whereby employees and consultants render services in
exchange for shares or rights over shares (‘equity-settled transactions’). The cost of these equity-settled
transactions with employees is measured by reference to the fair value at the date at which they are
granted. The fair value is determined by an internal valuation using a Black-Scholes option pricing
model.
The cost of equity-settled transactions is recognised, together with a corresponding increase in equity,
over the period in which the performance conditions are fulfilled, ending on the date on which the
relevant employees become fully entitled to the award (‘vesting date’).
The cumulative expense recognised for equity-settled transactions at each reporting date until vesting
date reflects (i) the extent to which the vesting period has expired and (ii) the number of awards that,
in the opinion of the Directors of the Company, will ultimately vest. This opinion is formed based on the
best available information at balance date. No adjustment is made for the likelihood of market
performance conditions being met as the effect of these conditions is included in the determination of
fair value at grant date.
No expense is recognised for awards that do not ultimately vest, except for awards where vesting is only
conditional upon a market condition. Where an equity-settled award is cancelled, it is treated as if it
had vested on the date of cancellation, and any expense not yet recognised for the award is
recognised immediately. However, if a new award is substituted for the cancelled award, and
designated as a replacement award on the date that it is granted, the cancelled and new award are
treated as if they were a modification of the original award.
44
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
(m) Cash and cash equivalents
For the purpose of the Statement of Cash Flows, cash and cash equivalents includes cash on hand,
deposits held at call with financial institutions, bank overdrafts and other short term, highly liquid
investments with original maturities of three months or less that are readily convertible to known amounts
of cash and which are subject to an insignificant risk of changes in value.
(n)
Interest income:
Interest income is recorded using the effective interest rate method (EIR). EIR is the rate that exactly
discounts the estimated future cash payments or receipts over the expected life of the financial
instrument, or a shorter period, where appropriate, to the net carrying amount of the financial asset or
liability. Interest income is included in finance income in the Statement of Comprehensive Income.
(o) Goods and services tax (GST)
Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of
GST incurred is not recoverable from the ATO. In these circumstances the GST is recognised as part of
the cost of acquisition of the asset or as part of the expense. Receivables and payables in the Statement
of Financial Position are shown inclusive of GST. Cash flows are presented in the Statement of Cash
Flows on a gross basis, except for the GST component of investing and financing activities, which are
disclosed as operating cash flows.
(p) Contributed equity
Ordinary issued share capital is recognised at the fair value of the consideration received by the
Company. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity
as a reduction in share proceeds received.
(q)
Trade and other payables
Liabilities for trade creditors and other amounts are subsequently carried at amortised cost after initial
recognition at fair value. Interest, when charged by the lender, is recognised as an expense on an
accrual basis.
(r)
Provisions
Provisions for legal claims and make good obligations are recognised when the Company has a
present legal or constructive obligation as a result of past events, it is probable that an outflow of
resources will be required to settle the obligation and the amount has been reliably estimated.
Provisions are not recognised for future operating losses.
Where there are a number of similar obligations, the likelihood that an outflow will be required in
settlement is determined by considering the class of obligations as a whole. A provision is recognised
even if the likelihood of an outflow with respect to any one item included in the same class of
obligations may be small.
Provisions are measured at the present value of management’s best estimate of the expenditure
required to settle the present obligation at the reporting date. The discount rate used to determine the
present value reflects current market assessments of the time value of money and the risks specific to
the liability. The increase in the provision due to the passage of time is recognised as interest expense.
(s)
Earnings per share
(i) Basic earnings per share
Basic earnings per share is calculated by dividing the result attributable to owners of the Company,
excluding any costs of servicing equity other than ordinary shares, by the weighted average number
of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares
issued during the year.
45
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
(ii) Diluted earnings per share
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to
take into account the after income tax effect of interest and other financing costs associated with
dilutive potential ordinary shares and the weighted average number of additional ordinary shares that
would have been outstanding assuming the conversion of all dilutive potential ordinary shares.
(t)
Financial instruments – initial recognition and subsequent measurement
(i)
Financial assets
Trade and other receivables are recognised initially at fair value and subsequently measured at
amortised cost using the effect interest method, less allowance for impairment. Trade receivables are
generally due for settlement within 30 days.
While the Company has policies in place to ensure that transactions with third parties have an
appropriate credit history, the management of current and potential credit risk exposures is limited as
far as is considered commercially appropriate. Up to the date of this Report, the Board has placed no
requirement for collateral on existing debtors. This is because the current Research and Development
Rebate Receivable is with the ATO, a reputable Australian government agency.
(ii)
Financial liabilities
Initial recognition and measurement
Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or
loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an
effective hedge, as appropriate. All financial liabilities are recognised initially at fair value and, in the
case of loans and borrowings and payables, net of directly attributable transaction costs. The
Company’s financial liabilities include trade and other payables.
The only financial liabilities the Company has are trade payables which we subsequently measured at
amortised cost using the EIR method. Refer to Note 12 for more detail.
Derecognition
A financial liability is derecognised when the obligation under the liability is discharged or cancelled or
expires.
(u)
Segment reporting
Operating segments are reported in a manner consistent with the internal reporting provided to the
chief operating decision maker. The chief operating decision maker, who is responsible for allocating
resources and assessing performance of the operating segments, has been identified as the Board of
Directors.
(v)
New accounting standards and interpretations adopted
Since 1 July 2019, Actinogen Medical has adopted all Accounting Standards and Interpretation,
mandatory for annual periods beginning on or before 1 July 2019.
Other than the adoption of AASB 16 (see below), the adoption of the new and amended accounting
standards and interpretations had no impact on the Company.
The Company has not early adopted any other accounting standard, interpretation or amendment
that has been issued but is not yet effective. The adoption of these standards, interpretations or
amendments is not expected to have a material impact on the financial position or performance of the
Company.
The Company has applied, for the first time, AASB 16 from 1 July 2019, and has not restated
comparatives for the prior period as permitted under the specific transition provisions in AASB 16. The
nature and effect of these changes are disclosed below.
46
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
AASB 16 Leases (AASB 16)
AASB 16 sets out the principles for the recognition, measurement, presentation and disclosure of leases
and requires lessees to account for most leases under a single on-balance sheet model.
The Company adopted AASB 16 using the modified retrospective method of adoption with the date of
initial application of 1 July 2019. Under this method, the standard is applied retrospectively with the
cumulative effect of initially applying the standard recognised at the date of initial application.
The Company elected to use the transition practical expedients allowing (a) the standard to be applied
only to contracts that were previously identified as leases applying AASB 117 and IFRIC 4 at the date of
initial application, and (b) the measuring the right-of-use asset on transition as being equal to the
amount of the lease liability initially recognised on transition.
The Company also elected to use the recognition exemptions for lease contracts that, at the
commencement date, had a lease term of 12 months or less and did not contain a purchase option
(‘short-term leases’), and lease contracts for which the underlying asset was of low value (‘low-value
assets’).
The lease liabilities as at 1 July 2019 can be reconciled to the operating lease commitments as of 30
June 2019 as follows:
i. The effect of adoption of AASB 16 is as follows:
The impact on the statement of financial position as at 1 July 2019 was an increase in right-of-use asset
of $467,613 and an increase in the lease liability of $467,613.
ii. Nature of the effect of adoption of AASB 16
The Company has lease contracts for property rental and an item of office equipment. Before the
adoption of AASB 16, the Company classified each of its leases (as lessee) at the inception date as an
operating lease (as it held no finance leases). In an operating lease, the leased property was not
capitalised and the lease payments were recognised as an expense in the statement of comprehensive
loss on a straight-line basis over the lease term. Prepaid rent was recognised under prepaid rental
expenses and accounts payable.
Upon adoption of AASB 16, the Company applied a single recognition and measurement approach for
all leases of which it was the lessee, except for short-term leases and leases of low-value assets. The
Company recognised lease liabilities to make lease payments and right-of-use assets representing the
right to use the underlying assets.
In accordance with the modified retrospective method of adoption of AASB 16, the Company applied
AASB 16 at the date of initial application by measuring the right-of-use assets based on the amount
equal to the lease liabilities. Lease liabilities were recognised based on the present value of the
remaining lease payments, discounted using the incremental borrowing rate at the date of initial
application.
47
$ Operating lease commitments as at 30 June 2019195,720 Weighted average incremental borrowing rate as at 1 July 20195.23%Discounted operating lease commitments at 1 July 2019185,754 Add:Option to extend for another three years281,859 Lease liabilities as at 1 July 2019467,613
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
iii. Summary of new accounting policies
Set out below are the new accounting policies of the Company upon adoption of AASB 16, which have
been applied from the date of initial application:
Right-of-use asset
The Company recognises a right-of-use asset at the commencement date of the lease (i.e., the date
the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated
depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost
of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and
lease payments made at or before the commencement date less any lease incentives received. Unless
the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term,
the recognised assets are depreciated on a straight-line basis over the shorter of its estimated useful life
and the lease term. A right-of-use asset is subject to impairment.
Lease liabilities
At the commencement date of the lease, the Company recognises lease liabilities measured at the
present value of lease payments to be made over the lease term. The lease payments include fixed
payments (including in-substance fixed payments) less any lease incentives receivable, variable lease
payments that depend on an index or a rate, and amounts expected to be paid under residual value
guarantees. The lease payments also include the exercise price of a purchase option reasonably certain
to be exercised by the Company and payments of penalties for terminating a lease, if the lease term
reflects the Company exercising the option to terminate. The variable lease payments that do not
depend on an index or a rate are recognised as expense in the period on which the event or condition
that triggers the payment occurs.
In calculating the present value of lease payments, the Company uses the incremental borrowing rate
at the lease commencement date if the interest rate implicit in the lease is not readily determinable.
After the commencement date, the amount of lease liabilities is increased to reflect the accretion of
interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed
lease payments or a change in the assessment to purchase the underlying asset.
Short-term leases and leases of low-value assets
The Company applies the short-term lease recognition exemption to its short-term leases (i.e., those
leases that have a lease term of 12 months or less from the commencement date and do not contain
a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office
equipment that are considered of low value (i.e., below USD$5,000). Lease payments on short-term
leases and leases of low-value assets are expensed on a straight-line basis over the lease term.
Significant judgement in determining the lease term of contracts with renewal options
The Company determines the lease term as the non-cancellable term of the lease, together with any
periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any
periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The
Company has the option under some of its leases to lease the assets for additional terms. The Company
applies judgement in evaluating whether it is reasonably certain to exercise the option to renew. That
is, it considers all relevant factors that create an economic incentive for it to exercise the renewal.
After the commencement date, the Company reassesses the lease term if there is a significant event or
change in circumstances that is within its control and affects its ability to exercise (or not to exercise)
the option to renew and renewal periods (e.g., a change in business strategy).
48
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
iv. Amounts recognised in the statements of financial position and comprehensive loss:
Set out below are the carrying amounts of the Company’s assets and lease liabilities recognised in the
statement of financial position and the movements during the year ended 30 June 2020:
i. The principal component of the $100,361 lease payments made during the year ended 30 June
2020 equates to $77,743 (which is net of $22,618 in interest expense paid).
ii. Of the total lease liability amounting to $389,870, $86,018 is current, and $303,852 is non-current.
Set out below are the amounts recognised in the statement of comprehensive loss for the year ended
30 June 2020:
(w) New accounting standards and interpretations not yet adopted
Certain new accounting standards and interpretations have been published that are not mandatory for 30
June 2020 reporting periods and have not been early adopted by the Company. These new standards and
interpretations, and the status of the Company’s assessment of impact on the Company, are set out below.
Reference
Title
Summary
AASB 3
Definition of
a Business -
Amendment
s to AASB 3
Key requirements
The AASB issued amendments to the definition of a business in AASB 3 Business
Combinations to help entities determine whether an acquired set of activities
and assets is a business or not. They clarify the minimum requirements for a
business, remove the assessment of whether market participants are capable
of replacing any missing elements, add guidance to help entities assess
whether an acquired process is substantive, narrow the definitions of a
business and of outputs, and introduce an optional fair value concentration
test.
Impact
The Company is not expecting any impact from the adoption of this Standard.
Application
date of
standard*
Application
date for
Company*
1 January 2020 1 July 2020
49
Right-of-use Assets PropertyTotalLease Liability$$$As at 1 July 2019- - - Initial adoption of AASB 16 467,613 467,613 467,613 Depreciation expense(95,112) (95,112) - Interest expense (i)- - 22,618 Payments (i)- - (100,361) As at 30 June 2020 (ii)372,501 372,501 389,870 As at30/06/2020$ Depreciation expense on right-of-use asset95,112 Interest expense on lease liabilities22,618 Rent expense - short-term leases(1,560) Total amounts recognised in profit or loss116,170
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
Reference
Title
Summary
AASB 101 and
AASB 108
Definition of
Material -
Amendment
s to AASB
101 and
AASB 108
Key requirements
In October 2018, the AASB issued amendments to AASB 101 Presentation of
Financial Statements and AASB 108 Accounting Policies, Changes in
Accounting Estimates and Errors to align the definition of ‘material’ across the
standards and to clarify certain aspects of the definition. The new definition
states that, ’Information is material if omitting, misstating or obscuring it could
reasonably be expected to influence decisions that the primary users of
general-purpose financial statements make on the basis of those financial
statements, which provide financial information about a specific reporting
entity.’
The amendments must be applied prospectively. Early application is
permitted and must be disclosed.
Impact
The amendments to the definition of material are not expected to have a
significant impact on a Company’s financial statements.
Application
date of
standard*
Application
date for
Company*
1 January 2020 1 July 2020
3.
FINANCIAL RISK MANAGEMENT
The Company’s activities expose it to a variety of financial risks: market risk, (including interest rate risk and
price risk), credit risk and liquidity risk. The Company’s overall risk in these areas is not significant enough to
warrant a formalised specific risk management program. Risk management is carried out by the Board of
Directors in their day-to-day function as the overseers of the business.
Set out below is an overview of the financial instruments held by the Company as at 30 June 2020:
50
Cash and cash equivalentsFinancial assets / liabilities at amortised costAs at 30/6/2020$$Financial assets:Cash and cash equivalents5,040,486 - Trade and other receivables- 3,123,428 Total current assets5,040,486 3,123,428 Total financial assets5,040,486 3,123,428 Financial liabilities:Trade and other payables- 509,275 Lease liabilities - current- 86,018 Total current liabilities- 595,293 Lease liabilities - non-current- 303,852 Total non-current liabilities- 303,852 Total financial liabilities- 899,145 Net exposure5,040,486 2,224,283
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
Set out below is an overview of the financial instruments held by the Company as at 30 June 2019:
(a) Market Risk
(i) Price risk
Equity price risk represents the risk that the value of a financial instrument will fluctuate as a result of changes
in equity prices, whether those changes are caused by factors specific to the individual instrument or its issuer
or factors affecting all instruments in the market.
(ii) Interest rate risk
The Company’s exposure to interest rate risk, which is the risk that a financial instrument’s value will fluctuate
as a result of changes in market interest rates and the interest rates on classes of financial assets and financial
liabilities is as follows:
Sensitivity analysis:
51
Cash and cash equivalentsFinancial assets / liabilities at amortised costAs at 30/6/2019$$Financial assets:Cash and cash equivalents7,636,601 - Trade and other receivables- 4,890,521 Total current assets7,636,601 4,890,521 Total assets7,636,601 4,890,521 Financial liabilities:Trade and other payables- 433,575 Total current liabilities- 433,575 Total liabilities- 433,575 Net exposure7,636,601 4,456,946-1%+1%Carrying amountProfit/EquityProfit/Equity30 June 2020$$$Financial AssetsCash and cash equivalents5,040,486(50,405) 50,405 30 June 2019Financial AssetsCash and cash equivalents7,636,601(76,366) 76,366 Interest rate risk
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
Variable rate instruments:
(b) Credit risk
Credit risk is the risk of financial loss to the Company if a counter party to a financial instrument fails to meet its
contractual obligations. The Company’s main credit risk exposure relates to the financial assets of the
Company, which comprise cash and cash equivalents and trade and other receivables. The Company’s
exposure to credit risk arises from potential default of the counter party, with the maximum exposure equal to
the carrying amount of these instruments.
The carrying amount of financial assets included in the Statement of Financial Position represents the
Company’s maximum exposure to credit risk in relation to those assets. The Company does not hold any credit
derivatives to offset its credit exposure.
The Company trades only with recognised, creditworthy third parties and as such collateral is not requested
nor is it the Company’s policy to securitise its trade and other receivables. Receivable balances are monitored
on an ongoing basis with the result that the Company does not have a significant exposure to bad debts.
The Company has the following concentrations of credit risk:
(i) Cash
The Directors believe that there is negligible credit risk with the Company’s cash and cash equivalents, as
funds are held at call with National Australia Bank, a reputable Australian Banking institution.
(ii) Trade and other receivables
While the Company has policies in place to ensure that transactions with third parties have an appropriate
credit history, the management of current and potential credit risk exposures is limited as far as is considered
commercially appropriate. Up to the date of this Report, the Board has placed no requirement for collateral
on existing debtors. This is because the current Research and Development Rebate Receivable is with the
ATO, a reputable Australian government agency.
(c)
Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its financial liabilities as and when they fall
due. Prudent liquidity risk management implies maintaining sufficient cash and marketable securities, the
availability of funding through an adequate amount of committed credit facilities and the ability to close out
market positions.
The Company manages liquidity risk by continuously monitoring forecast and actual cash flows. Surplus funds
are generally only invested at call or in bank bills that are highly liquid and with maturities of less than six months.
(i) Financing arrangements
The Company does not have any financing arrangements (2019: None).
(ii) Maturities of financial liabilities
The Company’s debt relates to trade and other payables, where payments are generally due within 30 days,
and lease liabilities.
The table below summarises the maturity profile of the Company’s financial liabilities based on contractual
undiscounted payments:
52
$%$%Cash and cash equivalents5,040,4860.757,636,6012.0320202019
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
(d)
Fair Value Measurements
The fair value of financial assets and financial liabilities must be estimated for recognition and measurement
or for disclosure purposes. Accounting standards require disclosure of fair value measurements by level of the
following fair value measurement hierarchy:
(a) quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1),
(b) inputs other than quoted prices included within level 1 that are observable for the asset or liability,
either directly (as prices) or indirectly (derived from prices) (level 2), and
(c) inputs for the asset or liability that are not based on observable market data (unobservable inputs)
(level 3).
The carrying value of financial assets and financial liabilities approximates their fair value as at 30 June 2020
and 30 June 2019 given the nature of the financial assets and liabilities.
4.
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS
•
Key estimates: Impairment of Intangible Assets
The Company assesses impairment for intangible assets at each reporting date or when an impairment
indicator exists, by evaluating conditions specific to the Company and to the particular asset that may lead
to impairment. These include product, technology, economic and political environments and future
expectations. If an impairment indicator exists, the recoverable amount of the asset is determined. For further
information on intangible assets refer to Note 2(h).
•
Key estimates: Share-based payments
The Company initially measures the cost of equity-settled transactions with employees by reference to the fair
value of the equity instruments at the date at which they are granted. Estimating fair value for share-based
payment transactions requires determination of the most appropriate valuation model, which is dependent
on the terms and conditions of the grant.
This estimate also requires determination of the most appropriate inputs to the valuation model including the
expected life of the share option, volatility and dividend yield and making assumptions about them. The
assumptions and models used for estimating fair value for share-based payment transactions are disclosed in
Note 20.
53
OnLess than3 to 121 to 5As at 30 June 2020demand3 monthsmonthsyears Total$$$$$Trade and other payables- 509,275 - - 509,275 Lease liabilities8,669 17,338 78,368 328,708 433,083 8,669 526,613 78,368 328,708 942,358 OnLess than3 to 121 to 5As at 30 June 2019demand3 monthsmonthsyears Total$$$$$Trade and other payables- 433,575 - - 433,575 - 433,575 - - 433,575
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
•
Significant Judgement: Research and development tax rebate
In line with accounting policy 2(i) research and development tax rebates are treated as government grants
and are recognised as income where there is reasonable assurance that the grant will be received, and all
attached conditions will be complied with. The Company applies judgment in assessing that all attached
conditions will be complied with based on the nature of the expenditure incurred and the activities of the
Company undertaken during the year.
5.
SEGMENT INFORMATION
The Company’s sole operations are within the biotechnology industry within Australia. Given the nature of the
Company, its size and current operations, the Company’s management does not treat any part of the
Company as a separate operating segment. Internal financial information used by the Company’s decision
makers is presented on a “whole of entity” manner without dissemination to any separately identifiable
segments.
Accordingly, the financial information reported elsewhere in this financial report is representative of the nature
and financial effects of the business activities in which it engages and the economic environments in which it
operates. All non-current assets are held in Australia and all income is derived in Australia.
6.
OTHER INCOME AND EXPENSES
54
Full year endedFull year ended30/06/202030/06/2019$ $IncomeInterest revenue 94,057 204,546 94,057 204,546 Other incomeGovernment grants 201,272 80,819 Research and development tax rebate 3,315,125 4,781,936Total other income 3,516,397 4,862,755 Total income 3,610,454 5,067,301 Full year endedFull year ended30/06/202030/06/2019$ $ExpensesResearch and Development Costs:Research consultants 249,948 228,427 Administrative 398,849 256,198 Laboratory expenses 4,888,373 10,410,646 5,537,170 10,895,271
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
7.
INCOME TAX
The tax benefit of tax losses and other deductible temporary differences will only arise in the future where the
Company derives sufficient net taxable income and is able to satisfy the carried forward tax loss recoupment
rules. The Directors believe that the likelihood of the Company achieving sufficient taxable income in the future
is currently not probable and the tax benefit of these tax losses and other temporary differences has not been
recognised.
55
Full-year endedFull-year ended30/06/202030/06/2019$ $Numerical reconciliation of operating loss to prima facie income tax expenseOperating loss before income tax (5,330,529)(9,887,682)Tax benefit at the Australian tax rate of 27.5% (2019: 27.5%)(1,465,895)(2,719,113)Tax effect of amounts that are not deductible / taxable in calculating taxable income:Non-deductible expenses940 1,274 ATO interest income327 - Share-based payments53,484 35,186 Deductible patent expenses - (8,827)Research and development912,1671,595,075Deferred income tax asset not brought to account498,9771,096,405Income tax expense - - Tax LossesUnused tax losses for which no deferred tax asset has been recognised.Potential tax benefit @ 27.5% (2019: 27.5%)3,826,1233,780,689 3,826,123 3,780,689 Unrecognised temporary differencesTemporary differences for which deferred tax assets have not been recognised.- Provisions and accruals180,663149,797- Intangible Assets790,502 476,900 - Capital raising costs534,436757,053- Patent application fees66,414 - - Legal expenses3,800 - - Fixed Assets (18,542) - 1,557,273 1,383,750 Unrecognised deferred tax asset relating to the above temporary differences @ 27.5% (2019: 27.5%) 428,250 380,531
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
8.
CASH AND CASH EQUIVALENTS
During the year ended 30 June 2020, the Company received interest revenue through holding several interest-
bearing term deposit accounts between 30 and 90 day terms. The Company is also expecting to receive an
estimated $2,482,699 which relates to the research and development rebate receivable recognised at year
end. For further information, refer to Note 9(c) below.
Reconciliation of net cash flows from operating activities
Non-cash financing and investing activities: During the year ended 30 June 2020, 3,000,000 unvested Class I LTI
Rights, totalling $120,000, were cancelled on 31 January 2020 for nil consideration. There were no other non-cash
financing and investing activities that occurred during the year ended 30 June 2020.
Financing facilities available: As at 30 June 2020, the Company had no financing facilities available (2019: None).
For the purposes of the Statement of Cash Flows, cash includes cash on hand and in banks and investments in
money market instruments, net of outstanding bank overdrafts.
Interest rate risk exposure: The Company’s exposure to interest rate risk is discussed in Note 3.
Credit risk exposure: The maximum exposure to credit risk at the end of the reporting period is the carrying
amount of each class of cash and cash equivalents mentioned above.
56
As atAs at30/06/202030/06/2019$ $Cash at bank and on hand1,475,4851,571,600Short term deposits 3,565,001 6,065,001Total cash and cash equivalents5,040,4867,636,601Full year endedFull year ended30/06/202030/06/2019$ $Loss for the year (5,330,529) (9,887,682)Non cash items:Depreciation (computer equipment) 4,219 - Depreciation (lease: office rental) 95,112 Amortisation expense 313,602 353,500 Impairment loss - 476,900 Share-based payment expense 194,488 127,949 Change in assets and liabilities:(Increase)/decrease in trade and other receivables 1,767,093 (1,358,107)Decrease in trade and other payables 75,700 (215,650)Increase in provisions 24,702 4,792 (2,855,613) (10,498,298)
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
9.
OTHER RECEIVABLES
(a) Prepayments: $60,175 relates to prepaid insurance and $400,845 is an R&D rebate portion calculated on
eligible expenditure incurred that relates to the manufacturing of consumables that have yet to be
received.
(b) Goods and services tax receivable: This amount related to net good and services tax (GST) paid during
the quarter ended 30 June 2020 which is refundable.
(c) Research and development tax rebate receivable: This amount related to the research and
development tax rebate that the Company is entitled to claim on research and development costs
incurred during the financial year.
None of the current receivables are impaired, or past due but not impaired. Due to their short-term nature,
carrying amounts approximate their fair value.
10.
PROPERTY, PLANT AND EQUIPMENT
Movements during the year:
No property, plant or equipment was held, acquired or disposed of during the prior year ended 30 June 2019.
57
As atAs at30/06/202030/06/2019$ $Prepayments (a) 461,020 57,115Goods and services tax receivable (b) 173,537 230,145Research and development tax rebate receivable (c) 2,482,699 4,603,261Other receivable 6,172 - Total other receivables3,123,4284,890,521As atAs at30/06/202030/06/2019$ $At cost 22,760 - Accumulated depreciation (4,219) - Total property, plant and equipment 18,541 - Computer EquipmentTotal$$Balance at 1 July 2019 - - Acquisitions 22,760 22,760 Depreciation (4,219) (4,219)Balance at 30 June 2020 18,541 18,541 Balance at 1 July 2018 - - Acquisitions - - Depreciation - - Balance at 30 June 2019 - -
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
11.
INTANGIBLE ASSETS
Movements during the year:
(a)
Intellectual property
On 8 December 2014, Actinogen Medical entered into an Assignment of Licence Agreement with Corticrine
Limited for the assignment of all of Corticrine’s interest in, to and under the Licence Agreement to Actinogen
Medical and the assumption by the Company of all of Corticrine's obligations in respect of such Assignment.
When the Company acquired the intellectual property from Corticrine, this comprised patents and licences,
as well as the value of research performed to date, and the progression of testing to human trials. The
intellectual property is supported by seven patent families, the most recent of which will expire in 2031. The
patent useful life has been aligned to the patent term and as a result, those patents are amortised on a
straight-line basis over the period of the patent. The remaining life of the patents and licenses is 11 years.
As at 30 June 2020, the Company assessed various internal and external sources of information to determine
whether an indication of impairment trigger existed. The Directors concluded that no impairment triggers
existed.
58
As atAs at30/06/202030/06/2019$ $ At cost 5,756,743 5,756,743 Accumulated amortisation (1,933,892)(1,620,290)Accumulated impairment loss (476,900) (476,900)Total intangible assets 3,345,951 3,659,553 Intellectual Property$ Balance at 1/7/2019 3,659,553 Amortisation expense (313,602)Impairment loss - Balance at 30/6/20203,345,951 Balance at 1/7/2018 4,489,953 Amortisation expense (353,500)Impairment loss (476,900)Balance at 30/6/2019 3,659,553
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
12.
TRADE AND OTHER PAYABLES
(a)
Trade payables are non-interest-bearing liabilities stated at amortised cost and settled within 30 days.
There was no provision for payroll tax due to instalments made during the year plus government
economic relief due to COVID-19, the Company is instead due a refund of $944 as at 30 June 2020.
(b) Accruals and other payables relates to $27,000 in accrued fees plus $400,845 in other payables that
relates to an R&D rebate amount (refer to Note 9 (a)) that the Company is expected to receive cash
proceeds for in the next financial year ended 30 June 2021, however, the liability will only be reversed
and recognised as income upon physical supply of drugs by a supplier of the Company.
13.
CONTRIBUTED EQUITY
(a) Reserve shares
Reserves shares (“LTI Rights” or “loan shares”) are ordinary shares that have historically been accounted for as
“in-substance options” under Australian Accounting Standards as they were issued with performance
conditions attached, covering both financial and non-financial measures of performance. No loan amount
was recognised in the prior year financial statements. As at 30 June 2020, there were no LTI Rights on issue.
Movement in reserve shares during the year were as follows:
59
As atAs at30/06/202030/06/2019$ $Trade payables (a) 46,841 282,822Accruals and other payables (b) 427,845 58,939Goods and services tax payable - 522 NAB credit cards - 33,542 Provision for payroll tax - 32,000 PAYG payable 34,589 25,750 Total trade and other payables 509,275 433,575As atAs at30/06/202030/06/2019$ $ Reserve shares - 480,000Total reserve shares - 480,000Reserve sharesDateQuantityUnit Price $Total $Opening balance 1 July 2018(40,000,000) (1,040,000) Repayment of loan shares by Mr Rogers30/11/201820,000,000 0.02400,000 Repayment of loan shares by Dr Loveridge6/12/20186,000,000 0.02120,000 Repayment of loan shares by Mr Ruffles15/03/20192,000,000 0.0240,000 Balance at 30 June 2019(12,000,000) (480,000) Repayment of loan shares by Dr Ketelbey9,000,000 0.04360,000 Cancellation of unvested loan shares3,000,000 0.04120,000 Balance at 30 June 2020- -
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
During the year, Dr Ketelbey repaid $360,000 attached to 6,000,000 Class H and 3,000,000 Class J LTI Rights.
The Company bought back the 3,000,000 Class I LTI Rights for nil consideration which released Dr Ketelbey
from the remaining $120,000.
(b) Fully paid ordinary shares
As at 30 June 2020 there were 1,116,231,320 fully paid ordinary shares of issue. Fully paid ordinary shares entitle
the holder to participate in dividends and the winding up of the Company in proportion to the number and
amount paid on the share held.
Movement of fully paid ordinary shares during the year were as follows:
(c) Share Options
60
As atAs at30/06/202030/06/2019$ $ Fully paid ordinary shares 51,318,15751,438,157Capital raising costs(3,393,551)(3,393,551)Total contributed equity47,924,60648,044,606DateQuantityUnit Price $Total $Opening balance at 1 July 2018940,316,55240,438,238Exercise of Unlisted Options4/07/20184,000,000 0.02 80,000Private Placement T2 (BVF)12/07/2018112,877,006 0.05 5,643,850Capital raising costs - Bell Potter12/07/2018(282,192)Share purchase plan13/07/201819,050,000 0.05 952,500Share purchase plan (shortfall)24/07/201811,200,000 0.05 560,000Capital raising costs - Bell Potter17/07/2018(35,056)Exercise of Unlisted Options18/09/20182,750,000 0.02 55,000Exercise of Unlisted Options14/11/201820,550,000 0.02 411,000Exercise of Unlisted Options30/11/20187,200,000 0.02 144,000Exercise of Unlisted Options4/04/20191,287,762 0.06 77,266Balance at 30 June 20191,119,231,32048,044,606Less cancelled unvested loan shares31/01/2020(3,000,000) (120,000) Balance at 30 June 20201,116,231,32047,924,606QuantityTypeGrant DateExercise PriceExpiry DateVesting Conditions2,100,000 Unlisted Employee Options A (Tranche 1)23/01/20170.100$ 5/02/2021Yes - fully vested5,000,000 Unlisted Director Options G24/03/20170.100$ 24/03/2022Yes - fully vested417,188 Unlisted Employee Options B (Tranche 2)12/07/20170.100$ 5/02/2021Upfront vesting1,500,000 Unlisted Director Options D18/01/20180.100$ 1/12/2022Yes1,042,110 Unlisted Employee Options C (Tranche 3)20/03/20180.100$ 5/02/2021Upfront vesting18,100,000 Unlisted Director Options F28/11/20180.085$ 27/11/2023Yes5,783,333 Unlisted Employee Options E (Tranche 4)12/12/20180.085$ 12/12/2023Yes5,000,000 Unlisted Consultant Options (Bio-Link)1/02/20190.093$ 1/02/2024Yes3,000,000 Unlisted Director Options H4/04/20190.100$ 4/04/2024Yes41,942,631 Total shares under option
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
As at 30 June 2020, there were 41,942,631 unissued ordinary shares under option. LTI Rights, although accounted
for as “in-substance options” due to the vesting conditions attached to them, are in fact issued ordinary shares
and therefore are not included in the table above. For further information on LTI Rights refer to Section 3C(iii) of
the Remuneration Report. During the year, no options were exercised, expired, lapsed or forfeited.
No option holder has any right, by virtue of the option, to participate in any share issue of the Company or any
related body corporate.
(d) Terms and Conditions of Issued Capital
At shareholders’ meetings each ordinary share is entitled to one vote when a poll is called, otherwise each
shareholder has a vote on a show of hands. Ordinary shares have no par value.
(e) Capital risk management
The Company’s objectives when managing capital are to safeguard its ability to continue as a going concern,
so it can provide returns to shareholders and benefits to other stakeholders. The Company considers capital
to consist of cash reserves on hand.
Consistent with the Company’s objective, it manages working capital by issuing new shares, investing in and
selling assets, submitting applications for research and development rebates to the Australian Tax Office or
modifying its planned research and development program as required.
Given the stage of the Company’s development there are no formal targets set for return on capital. The
Company is not subject to externally imposed capital requirements. The net equity of the Company is
equivalent to capital. Net capital is obtained through capital raisings on the ASX and receipt of Research
and Development rebates from the Australian Tax Office.
14.
RESERVES
Reserves are made up of the option reserve. The option reserve records items recognised as share-based
payment (‘SBP’) expenses for employee and Director options. Details of the movement in reserves is shown
below.
Movements in Option Reserve during the year:
Refer to Note 13(d) on unissued ordinary shares under option and Note 20: Share-based payments.
61
As atAs at30/06/202030/06/2019$ $Option Reserve7,490,7457,296,257Total reserves7,490,7457,296,257As atAs at30/06/202030/06/2019$ $Option ReserveBalance at the beginning of the year7,296,2577,168,308Share-based payment expense on Director options 127,419 102,896 Share-based payment expense on employee options30,020 36,571 Lapse of employee options - (22,834)Share-based payment expense on consultant options 37,049 11,316 Balance at end of year7,490,7457,296,257
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
15.
LOSSES PER SHARE
As at 30 June 2020, there were 41,942,631 (2019: 41,942,631) unissued ordinary shares under option excluded
from the calculation of diluted earnings per share that could potentially dilute basic earnings per share in the
future but are anti-dilutive for the current period presented. There have been no other transactions involving
ordinary shares or potential ordinary shares between the reporting date and the date of authorisation of these
financial statements.
16.
REMUNERATION OF AUDITOR
17.
CONTINGENCIES
The Directors are not aware of any contingent liabilities or assets as at 30 June 2020 (2019: Nil). Research and
development claims recognised are subject to review within the time period stipulated by the Australian Tax
Office (‘ATO’).
62
Full-year endedFull-year ended30/06/202030/06/2019$ $Basic loss per share from continuing operations attributable to the ordinary shareholders of the Company (cents)(0.48) (0.90) Weighted number of ordinary shares used as the denominator1,117,982,005 1,102,236,780 Net loss used in calculating loss per share(5,330,529) (9,887,682) Diluted loss per share from continuing operations attributable to the ordinary shareholders of the Company (cents)(0.48) (0.90) Weighted number of ordinary shares used as the denominator1,117,982,005 1,102,236,780 Net loss used in calculating diluted loss per share(5,330,529) (9,887,682) Full-year endedFull-year ended30/06/202030/06/2019$ $Amounts paid or payable to Ernst & Young for:An audit or review of the financial statements of the entity 40,800 41,903 Other assurance services 2,600 2,500 43,400 44,403
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
_________________________________________________________________
18.
KEY MANAGEMENT PERSONNEL DISCLOSURES
Key Management Personnel (“KMP”) of Actinogen Medical and their compensation during the year are listed
below:
There were no other long-term benefits or termination benefits paid out during the years ended 30 June 2020 and
30 June 2019. The detailed remuneration disclosures and relevant interest of each KMP in fully paid ordinary shares
and options of the Company are provided in the audited Remuneration Report on pages 21 to 34.
19.
RELATED PARTY TRANSACTIONS
There were no related party transactions that occurred during the year other than transactions with KMP as set
out in Note 18.
63
NamePositionAppointedResignedDr Geoffrey BrookeNon-Executive Chairman1/03/2017CurrentDr Bill KetelbeyManaging Director / Chief Executive Officer18/12/2014CurrentDr George MorstynNon-Executive Director1/12/2017CurrentMr Malcolm McComasNon-Executive Director4/04/2019CurrentFull-year endedFull-year ended30/06/202030/06/2019$ $Short-term employee benefits 590,894 584,405 Post employment benefits 33,095 29,207 Long-term benefits 26,660 11,388 Share-based payments 127,420 102,897 778,069 727,897
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
20.
SHARE – BASED PAYMENTS
The table below summarises the options on issue (including the LTI Rights that were in substance options held during the year) that had share-based payments applied as at
30 June 2020:
Common to all classes of options on issue are the following factors and assumptions:
•
The fair value of options granted have been valued using a Black-Scholes option pricing model, taking into account the terms and conditions upon which the share
options were granted. Where vesting conditions are applicable, they are expensed over the vesting period.
The assumed dividend payable during the term of the Options is deemed to be nil.
•
• A volatility of the share price fluctuation was calculated by considering the historical movement of the share price over a period of time as well factoring market
conditions of its competitors to predict the distribution of relative share performance.
The exercise price of the share options is equal to the market price of the underlying shares on the date of grant.
The Company does not have a past practice of cash settlement or cash settlement alternatives for these awards.
•
•
64
QuantityTypeGrantDateExercise PriceExpiry DateRemaning life (years)Vesting ConditionsReference below- LTI Rights Class H to J15/12/20140.04$ 15/12/20190Fully vested.(a)2,100,000 Employee Options (A) (Tranche 1)23/01/20170.10$ 5/02/20211Fully vested.(b)417,188 Employee Options (B) (Tranche 2)12/07/20170.10$ 5/02/20211No. Upfront vesting.417,110 Employee Options (C) (Tranche 3)20/03/20180.10$ 5/02/20211No. Upfront vesting.625,000 Employee Options (C) (Tranche 3)20/03/20180.10$ 5/02/20211Fully vested.5,783,333 Employee Options (E) (Tranche 4)12/12/20180.085$ 12/12/20233Yes1,500,000 Director Options (D)18/01/20180.10$ 1/12/20222Yes(c)18,100,000 Director Options (F)28/11/20180.085$ 27/11/20233Yes5,000,000 Director Options (G)24/03/20170.10$ 24/03/20255Fully vested.3,000,000 Director Options (H)4/04/20190.100$ 4/04/20244Yes5,000,000 Consultant Options1/02/20190.093$ 1/02/20244Yes(d)41,942,631 Total quantity of share-based payments
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
(a) LTI Rights
The LTI Rights on issue during the year were fully expensed in prior reporting years, therefore, no share-based payment expense was recognised during the year.
At the beginning of the year the total loan value of the 12,000,000 LTI Rights (“Loan shares”) outstanding was $480,000 which related to Dr Ketelbey’s Class H, I and J LTI
Rights. During the year, Dr Ketelbey repaid $360,000 attached to 6,000,000 Class H and 3,000,000 Class J LTI Rights. The remaining 3,000,000 Class I LTI Right had market-
based vesting conditions attached to them that went unmet in a prior period. In January 2020, The Company decided to buy-back and cancel the 3,000,000 shares and
release Dr Ketelbey from the obligation to repay the remaining $120,000 share loan advance attached to them.
As at 30 June 2020, there were no LTI Rights (“Loan shares”) on issue.
These shares were considered to be “in substance options’ or rights (‘LTI Rights’) under Australian Accounting Standards, were issued to various KMP at the time by way of
provision of a limited recourse loan. They were independently valued using the Black-Scholes option pricing model taking into account the terms and conditions upon which
the LTI Rights were granted. Due to the vesting conditions attached to these LTI Rights, they have been fully expensed in prior reporting years over the vesting periods
applicable.
The fair value of options granted during a prior year ended 30 June 2015 was estimated on the date of grant using the following assumptions:
Expected volatility (%) 100
Risk-free interest rate (%) 5.0%
Expected life (years) 5.0
• Dividend yield (%) nil
•
•
•
• Weighted average share price ($) 0.04
•
The approximate interest rate over a five-year term was used.
65
RecipientGrant DateClassQuantity of LTI rights as at 1 July 2019Quantity of LTI Rights converted during the year (Note 13a)Quantity of LTI Rights cancelled during the year (Note 13a)Quantity of LTI Rights as at 30 June 2020Fair value per LTI RightTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value of converted rights during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsB. Ketelbey15/12/2014Class H6,000,000 (6,000,000) - - $ 0.0365 218,886$ 218,886$ -$ -$ 218,886$ -$ B. Ketelbey15/12/2014Class I3,000,000 - (3,000,000) - 0.0365$ 109,443$ 109,443$ -$ -$ 109,443$ -$ B. Ketelbey15/12/2014Class J3,000,000 (3,000,000) - - 0.0365$ 109,443$ 109,443$ -$ -$ 109,443$ -$ Total Rights12,000,000 (9,000,000) (3,000,000) - 437,772$ 437,772$ -$ -$ 437,772$ -$
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
(b) Employee Options A, B, C and E
Under the Employee Option Plan (approved by shareholders on 12 November 2015), awards are made to employees of the Company. The Plan awards are delivered in the
form of options over shares.
During the year and in previous years, various issues of options to employees were made and are outlined below.
(i)
4,950,000 Employee Options (A)
The Employee Options (A) on issue were fully expensed in prior reporting years, therefore, no share-based payment expense was recognised during the year.
The fair value of options granted during a prior year ended 30 June 2017 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 100%
Risk-free interest rate (%) 2.17%
Expected life (years) 5.0
The approximate interest rate over a five-year term was used.
66
RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsV. Ruffles23/01/20171,250,000 - 1,250,000 0.0352$ 44,000$ 44,000$ -$ -$ 44,000$ -$ T. Woolley23/01/2017200,000 - 200,000 0.0352$ 7,040$ 7,040$ -$ -$ 7,040$ -$ P. Webse23/01/2017300,000 - 300,000 0.0352$ 10,560$ 10,560$ -$ -$ 10,560$ -$ T. Russell23/01/2017100,000 - 100,000 0.0352$ 3,520$ 3,520$ -$ -$ 3,520$ -$ B. Rooney23/01/2017250,000 - 250,000 0.0352$ 8,800$ 8,800$ -$ -$ 8,800$ -$ Total2,100,000 - 2,100,000 73,920$ 73,920$ -$ -$ 73,920$ -$
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
(ii)
417,188 Employee Options (B)
The Employee Options (B) on issue were fully expensed in prior reporting years, therefore, no share-based payment expense was recognised during the year. There were no
vesting conditions attached to these options, therefore, the total share-payment of $10,188 was fully expensed as at grant date.
The fair value of options granted during the prior year ended 30 June 2018 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 75%
Risk-free interest rate (%) 2.29%
Expected life (years) 4.0
The approximate interest rate over a four-year term was used.
Although Mr Ruffles is no longer an employee of the Company, his 234,375 unlisted options that vested during his employment with the Company remain on issue.
(iii)
1,354,610 Employee Options (C)
The Employee Options (C) on issue were fully expensed in prior reporting years, therefore, no share-based payment expense was recognised during the year.
The fair value of options granted during the prior year ended 30 June 2018 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 65%
Risk-free interest rate (%) 2.101%
Expected life (years) 3.0
The approximate interest rate over a three-year term was used.
67
RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsV. Ruffles12/07/2017234,375 - 234,375 0.0244$ 5,723$ 5,723$ -$ - 5,723$ - T. Russell12/07/201718,750 - 18,750 0.0244$ 458$ 458$ -$ - 458$ - K. Boyd12/07/2017117,188 - 117,188 0.0244$ 2,862$ 2,862$ -$ - 2,862$ - B. Rooney12/07/201746,875 - 46,875 0.0244$ 1,145$ 1,145$ -$ - 1,145$ - Total417,188 - 417,188 10,188$ 10,188$ -$ -$ 10,188$ -$
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
Although Mr Ruffles is no longer an employee of the Company, his 296,875 unlisted options that vested during his employment with the Company remain on issue.
(iv)
6,700,000 Employee Options (E)
The fair value of options granted during the year ended 30 June 2019 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 54%
Risk-free interest rate (%) 2.15%
Expected life (years) 5.0
The approximate interest rate over a five-year term was used.
Although Mr Ruffles is no longer an employee of the Company, the 83,333 unlisted options that vested during his employment with the Company remain on issue.
68
RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsV. Ruffles20/03/2018296,875 - 296,875 0.0128$ 3,804$ 3,804$ -$ -$ 3,804$ -$ T. Russell20/03/201823,750 - 23,750 0.0128$ 304$ 304$ -$ -$ 304$ -$ T. Miller20/03/2018662,110 - 662,110 0.0128$ 8,485$ 8,485$ -$ -$ 8,485$ - B. Rooney20/03/201859,375 - 59,375 0.0128$ 761$ 761$ -$ -$ 761$ -$ Total1,042,110 - 1,042,110 13,354$ 13,354$ - - 13,354$ - RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsV. Ruffles12/12/201883,333 - 83,333 0.0158$ 15,800$ 1,317$ -$ -$ 1,317$ -$ T. Miller12/12/20184,000,000 - 4,000,000 0.0158$ 63,200$ 10,533$ 21,067$ -$ 31,600$ 31,600$ M. Roesner12/12/20181,000,000 - 1,000,000 0.0158$ 15,800$ 2,633$ 5,267$ -$ 7,900$ 7,900$ T. Russell12/12/2018200,000 - 200,000 0.0158$ 3,160$ 527$ 1,053$ -$ 1,580$ 1,580$ T. Woolley12/12/2018200,000 - 200,000 0.0158$ 3,160$ 527$ 1,053$ -$ 1,580$ 1,580$ P. Webse12/12/2018300,000 - 300,000 0.0158$ 4,740$ 790$ 1,580$ -$ 2,370$ 2,370$ Total5,783,333 - 5,783,333 105,860$ 16,327$ 30,020$ -$ 46,347$ 45,030$
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
(c) Director Options
Additional information relating to Director Options can be found in Section 3(C)(b) of the Remuneration Report which is located within the Directors’ Report.
(i)
1,500,000 Director Options (D) - Issued to Dr George Morstyn
1,500,000 Director options were granted to Dr George Morstyn as part of his appointment to the Board as Non-Executive Director. These options over shares will vest over a
period of three years subject to meeting various vesting conditions. Refer to Section 3(C)(b) within the Remuneration Report for further information on vesting conditions.
The fair value of options granted during the prior year ended 30 June 2018 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 60%
Risk-free interest rate (%) 2.44%
Expected life (years) 5.0
The approximate interest rate over a five-year term was used.
(ii)
18,100,000 Director Options (F) – issued to various Directors
18,100,000 Director options were granted to various Directors who held office at the time of the date of grant. These options over shares will vest quarterly over a period of
three years subject to continuous service as a director from grant date up to and including each of the quarterly vesting dates.
The fair value of options granted during the year ended 30 June 2019 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 54%
Risk-free interest rate (%) 2.29%
Expected life (years) 5.0
The approximate interest rate over a five-year term was used.
69
RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsG. Morstyn18/01/2018700,000 - 700,000 0.0129$ 9,030$ 9,030$ -$ -$ 9,030$ -$ G. Morstyn18/01/2018400,000 - 400,000 0.0129$ 5,160$ 4,071$ 1,089$ -$ 5,160$ -$ G. Morstyn18/01/2018400,000 - 400,000 0.0129$ 5,160$ 2,712$ 1,723$ -$ 4,435$ 725$ Total1,500,000 - 1,500,000 19,350$ 15,813$ 2,812$ -$ 18,625$ 725$
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
(iii)
5,000,000 Director Options (G) - Issued to Dr Geoffrey Brooke
5,000,000 Director options were granted to Dr Geoffrey Brooke as part of his appointment to the Board as Non-Executive Chairman. The Director Options (G) on issue were
fully expensed in prior reporting years, therefore, no share-based payment expense was recognised during the year.
The fair value of options granted during a prior year ended 30 June 2017 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 100
Risk-free interest rate (%) 2.61%
Expected life (years) 8.0
The approximate interest rate over a five-year term was used.
70
RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsG. Brooke28/11/20184,900,000 - 4,900,000 0.0142$ 69,580$ 11,597$ 23,193$ -$ 34,790$ 34,790$ B. Ketelbey28/11/201811,700,000 - 11,700,000 0.0142$ 166,140$ 27,690$ 55,380$ -$ 83,070$ 83,070$ G. Morstyn28/11/20181,500,000 - 1,500,000 0.0142$ 21,300$ 3,550$ 7,100$ -$ 10,650$ 10,650$ Total18,100,000 - 18,100,000 257,020$ 42,837$ 85,673$ - 128,510$ 128,510$ RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsG. Brooke24/03/20175,000,000 - 5,000,000 0.0491$ 245,285$ 220,483$ 24,803$ -$ 245,286$ -$ Total5,000,000 - 5,000,000 245,285$ 220,483$ 24,803$ -$ 245,286$ -$
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
(iv)
3,000,000 Director Options (H) - Issued to Mr Malcolm McComas
3,000,000 Director options were granted to Mr McComas as part of his appointment to the Board as Non-Executive Director. These options over shares will vest quarterly over
a period of three years subject to continuous service as a director from grant date up to and including each of the quarterly vesting dates.
The fair value of options granted during the year ended 30 June 2019 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 48.5
Risk-free interest rate (%) 1.5%
Expected life (years) 5.0
The approximate interest rate over a five-year term was used.
71
RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsM. McComas4/04/20193,000,000 - 3,000,000 0.0141$ 42,396$ 3,533$ 14,132$ -$ 17,665$ 24,731$ Total3,000,000 - 3,000,000 42,396$ 3,533$ 14,132$ -$ 17,665$ 24,731$
ACTINOGEN MEDICAL LIMITED
N O T E S T O T H E F I N A N C I A L S T A T E M E N T S
3 0 J U N E 2 0 2 0
(d) Consultant Options
(i)
Issued to Bio-Link Australia
5,000,000 options were granted to Bio-Link Australia to reward them for their existing contributions to the Company, and to incentivise future achievements that will benefit
shareholders. These options over shares will vest over a period of four years subject to meeting various vesting conditions.
The fair value of options granted during the year ended 30 June 2019 was estimated on the date of grant using the following assumptions:
• Dividend yield (%) nil
•
•
•
•
Expected volatility (%) 53.75%
Risk-free interest rate (%) 1.83%
Expected life (years) 5.0
The approximate interest rate over a five-year term was used.
21.
EVENTS OCCURRING AFTER THE REPORTING PERIOD
There are no matters or circumstances that have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the
Company, the results of those operations, or the state of the Company in subsequent financial years.
72
RecipientGrant DateQuantity as at 1 July 2019Quantity issued / (lapsed) during the year Quantity as at 30 June 2020Fair value per optionTotal SBP valuationOpening value of SBP expensed as at 1 July 2019Value recognised during the year Value lapsed during the year Closing value of SBP expensed as at 30 June 2020Value to be recognised in future yearsBio-Link1/02/2019500,000 - 500,000 0.0185$ 9,250$ -$ 9,250$ -$ 9,250$ -$ Bio-Link1/02/20191,500,000 - 1,500,000 0.0185$ 27,750$ 5,656$ 13,894$ -$ 19,550$ 8,200$ Bio-Link1/02/20193,000,000 - 3,000,000 0.0185$ 55,500$ 5,660$ 13,904$ -$ 19,564$ 35,936$ Total5,000,000 - 5,000,000 92,500$ 11,316$ 37,048$ -$ 48,364$ 44,136$
ACTINOGEN MEDICAL LIMITED
DIRECTORS’ DECLARATION
In the Directors’ opinion:
1.
The Financial Statements and Notes set out on pages 37 to 72, are in accordance with the
Corporations Act 2001 including:
(a) complying with Accounting Standards, the Corporations Regulations 2001 and other
mandatory professional reporting requirements,
(b) giving a true and fair view of the Company’s financial position as at 30 June 2020 and of
its performance for the year ended on that date,
The remuneration disclosure included in the audited Remuneration Report in the Directors’
Report complies with Section 300A of the Corporations Act 2001.
The Directors have been given the declaration by the Managing Director and Chief Financial
Officer (or equivalent) as required by section 295A of the Corporations Act 2001.
The Company has included in the Notes to the Financial Statements an explicit and unreserved
statement of compliance with International Financial Reporting Standards as issued by the
International Accounting Standards Board.
2.
3.
4.
5.
There are reasonable grounds to believe that the Company will be able to pay its debts as and
when they become due and payable.
This declaration is made in accordance with a resolution of the Directors.
Dr Bill Ketelbey
Managing Director
Sydney, New South Wales
26 August 2020
73
Ernst & Young
11 Mounts Bay Road
Perth WA 6000 Australia
GPO Box M939 Perth WA 6843
Tel: +61 8 9429 2222
Fax: +61 8 9429 2436
ey.com/au
Independent auditor's report to the members of Actinogen Medical
Limited
Report on the audit of the financial report
Opinion
We have audited the financial report of Actinogen Medical Limited (the Company), which comprises the
statement of financial position as at 30 June 2020, the statement of comprehensive income, statement
of changes in equity and statement of cash flows for the year then ended, notes to the financial
statements, including a summary of significant accounting policies, and the directors' declaration of the
Company.
In our opinion, the accompanying financial report of the Company is in accordance with the Corporations
Act 2001, including:
a)
giving a true and fair view of the Company's financial position as at 30 June 2020 and of its
financial performance for the year ended on that date; and
b)
complying with Australian Accounting Standards and the Corporations Regulations 2001.
Basis for opinion
We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under
those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial
Report section of our report. We are independent of the Company in accordance with the auditor
independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting
Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants
(including Independence Standards) (the Code) that are relevant to our audit of the financial report in
Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for
our opinion.
Key audit matters
Key audit matters are those matters that, in our professional judgment, were of most significance in our
audit of the financial report of the current year. These matters were addressed in the context of our audit
of the financial report as a whole, and in forming our opinion thereon, but we do not provide a separate
opinion on these matters. For each matter below, our description of how our audit addressed the matter
is provided in that context. We have determined the matters described below to be the key audit matters
to be communicated in our report.
We have fulfilled the responsibilities described in the Auditor’s responsibilities for the audit of the financial
report section of our report, including in relation to these matters. Accordingly, our audit included the
performance of procedures designed to respond to our assessment of the risks of material misstatement
of the financial report. The results of our audit procedures, including the procedures performed to
address the matters below, provide the basis for our audit opinion on the accompanying financial report.
A member firm of Ernst & Young Global Limited
Liability limited by a scheme approved under Professional Standards Legislation
PD:JG:ACW:009
1. Research and development rebate
Why significant
How our audit addressed the key audit matter
The Company has lodged a claim with the Australian Taxation
Office (ATO) for a rebate of eligible Research & Development
(R&D) expenditure (R&D rebate) relating to its ongoing
research activities for the development of Xanamem.
Included in trade and other receivables on the statement of
financial position is an amount for $2.48 million related to the
R&D rebate calculated for the year ended 30 June 2020.
Due to judgment involved in determining whether expenditure
incurred in R&D activities meets the eligibility criteria to qualify
for inclusion in the R&D rebate calculation and the significance
of this source of cash inflow for the Company, we considered
this to be a key audit matter. Refer to Note 9 of the financial
report.
2. Carrying value of intangible assets
We involved our R&D taxation specialists to assess the
appropriateness of the R&D rebate calculated by the
Company’s third party expert.
We evaluated the qualifications, competency and objectivity of
the Company’s third party expert.
We assessed the Company’s accounting treatment of the R&D
rebate under Australian Accounting Standard - AASB 120
Accounting for Government Grants and Disclosure of
Government Assistance.
Why significant
How our audit addressed the key audit matter
Included in the statement of financial position as at 30 June
2020 is an amount for $3.35 million relating to intangible
assets which consist of patents and licenses. This amount
represents 28% of the Company’s total assets.
The carrying value of intangible assets must be assessed for
impairment when facts and circumstances indicate that the
carrying value exceeds its recoverable amount.
Following an assessment of a number of internal and external
factors, the directors determined that there were no
impairment indicators present at 30 June 2020.
Due to the significance to the Company’s financial report and
the high degree of judgment involved in determining whether
indicators of impairment were present, we consider this to be a
key audit matter. Refer to Note 11 of the financial report.
We challenged the appropriateness of the Company’s
assessment and conclusion that there were no impairment
indicators present as at 30 June 2020.
In doing so, we examined the patent and licence agreements,
considered internal and external impairment factors and
assessed the appropriateness of the amortisation period of the
patents and licences pursuant to the requirements of
Australian Accounting Standards.
We assessed the adequacy of the disclosures in Note 11 to the
financial report.
Information other than the financial report and auditor’s report
The directors are responsible for the other information. The other information comprises the information
included in the Company’s 2020 Annual Report, but does not include the financial report and our
auditor’s report thereon.
Our opinion on the financial report does not cover the other information and accordingly we do not
express any form of assurance conclusion thereon, with the exception of the Remuneration Report and
our related assurance opinion.
In connection with our audit of the financial report, our responsibility is to read the other information and,
in doing so, consider whether the other information is materially inconsistent with the financial report or
our knowledge obtained in the audit or otherwise appears to be materially misstated.
If, based on the work we have performed, we conclude that there is a material misstatement of this other
information, we are required to report that fact. We have nothing to report in this regard.
A member firm of Ernst & Young Global Limited
Liability limited by a scheme approved under Professional Standards Legislation
Responsibilities of the directors for the financial report
The directors of the Company are responsible for the preparation of the financial report that gives a true
and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for
such internal control as the directors determine is necessary to enable the preparation of the financial
report that gives a true and fair view and is free from material misstatement, whether due to fraud or
error.
In preparing the financial report, the directors are responsible for assessing the Company’s ability to
continue as a going concern, disclosing, as applicable, matters relating to going concern and using the
going concern basis of accounting unless the directors either intend to liquidate the Company or to cease
operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial report
Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free
from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes
our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit
conducted in accordance with the Australian Auditing Standards will always detect a material
misstatement when it exists. Misstatements can arise from fraud or error and are considered material if,
individually or in the aggregate, they could reasonably be expected to influence the economic decisions of
users taken on the basis of this financial report.
As part of an audit in accordance with the Australian Auditing Standards, we exercise professional
judgment and maintain professional scepticism throughout the audit. We also:
►
Identify and assess the risks of material misstatement of the financial report, whether due to fraud or
error, design and perform audit procedures responsive to those risks, and obtain audit evidence that
is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material
misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve
collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
► Obtain an understanding of internal control relevant to the audit in order to design audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Company’s internal control
► Evaluate the appropriateness of accounting policies used and the reasonableness of accounting
estimates and related disclosures made by the directors
► Conclude on the appropriateness of the directors’ use of the going concern basis of accounting and,
based on the audit evidence obtained, whether a material uncertainty exists related to events or
conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If
we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s
report to the related disclosures in the financial report or, if such disclosures are inadequate, to
modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our
auditor’s report. However, future events or conditions may cause the Company to cease to continue
as a going concern
A member firm of Ernst & Young Global Limited
Liability limited by a scheme approved under Professional Standards Legislation
► Evaluate the overall presentation, structure and content of the financial report, including the
disclosures, and whether the financial report represents the underlying transactions and events in a
manner that achieves fair presentation
We communicate with the directors regarding, among other matters, the planned scope and timing of the
audit and significant audit findings, including any significant deficiencies in internal control that we
identify during our audit.
We also provide the directors with a statement that we have complied with relevant ethical requirements
regarding independence, and to communicate with them all relationships and other matters that may
reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate
threats or safeguards applied.
From the matters communicated to the directors, we determine those matters that were of most
significance in the audit of the financial report of the current year and are therefore the key audit
matters. We describe these matters in our auditor’s report unless law or regulation precludes public
disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should
not be communicated in our report because the adverse consequences of doing so would reasonably be
expected to outweigh the public interest benefits of such communication.
Report on the audit of the remuneration report
Opinion on the remuneration report
We have audited the Remuneration Report included in pages 21 to 34 of the directors' report for the year
ended 30 June 2020.
In our opinion, the Remuneration Report of the Company for the year ended 30 June 2020, complies with
section 300A of the Corporations Act 2001.
Responsibilities
The directors of the Company are responsible for the preparation and presentation of the Remuneration
Report in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an
opinion on the Remuneration Report, based on our audit conducted in accordance with Australian
Auditing Standards.
Ernst & Young
Pierre Dreyer
Partner
Perth
26 August 2020
A member firm of Ernst & Young Global Limited
Liability limited by a scheme approved under Professional Standards Legislation
ACTINOGEN LIMITED
S H A R E H O L D E R I N F O R M A T I O N
___________________________________________________________
Substantial shareholders
The following substantial shareholders have lodged notices with the company as at 5 October 2020:
Holders
BVF Partners L.P. on its own behalf and on behalf of BVF Inc.,
Mark N Lampert, Biotechnology Value Fund, L.P., and
Biotechnology Value Fund II, L.P.
Distribution of ordinary shareholders as at 5 October 2020
Shares
Percentage of
Issued Capital
217,200,000
19.46%
Range of Holding
1-1,000
1,001-5,000
5,001-10,000
10,001 - 100,000
100,001 – over
Shareholders with less than a
marketable parcel.
Shares
6,915
283,655
1,992,705
68,922,872
1,045,025,173
1,116,231,320
Holders
58
92
225
1,562
1,031
2,968
652
Voting Rights
Each fully paid ordinary share carries voting rights of one vote per share.
Twenty Largest holders of quoted ordinary shares as at 5 October 2020
HSBC Custody Nominees (Australia) Limited
Edinburgh Technology Fund Limited
Surfit Capital Pty Ltd
Tisia Nominees Pty Ltd
Mrs Sarah Cameron
Brazil Farming Pty Ltd
Citicorp Nominees Pty Ltd
Mr Steven Veronese
Oaktone Nominees Pty Ltd
Mrs Gillian Karen Nes & Mrs Ronald Nes
Kaleidoscope Holdings Pty Ltd
Griffin & Grace Investments Pty Ltd
Mr Peter James Nixon
Alua Capital Pty Ltd
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd DRP
BNP Parabis Nominees Pty Ltd
Bannaby Investments Pty Ltd
Romfal Sifat Pty Ltd
Webinvest Pty Ltd
Paranji Super Fund Pty Ltd
TOTAL
Number of
Shares
227,303,623
48,147,864
30,000,000
27,867,184
25,916,573
15,000,000
10,604,474
10,008,001
10,000,000
9,950,000
9,000,000
8,800,000
8,400,000
8,000,000
7,738,901
7,560,729
7,500,000
7,000,000
7,000,000
6,500,000
492,297,349
Percentage
of Issued
Capital
20.36%
4.31%
2.69%
2.50%
2.32%
1.34%
0.95%
0.90%
0.90%
0.89%
0.81%
0.79%
0.75%
0.72%
0.69%
0.68%
0.67%
0.63%
0.63%
0.58%
44.10%
78
ACTINOGEN LIMITED
S H A R E H O L D E R I N F O R M A T I O N
___________________________________________________________
Unquoted Securities as at 5 October 2020
There were 3,559,298 unlisted employee share option plan options exercisable at $0.10 each and
expiring on 5 February 2021 held by seven holders, on issue.
There were 1,500,000 unlisted options exercisable at $0.10 each and expiring on 1 December
2022 held by one holder, on issue. Details of the holders holding more than 20% of the above:
George Morstyn
Number of Options
Percentage
1,500,000
100.00%
There were 18,100,000 unlisted options exercisable at $0.085 each and expiring on 27 November
2023 held by three holders, on issue. Details of the holders holding more than 20% of the above:
John William Ketelbey
Geoffrey Edward Duncan Brooke
Number of Options
Percentage
11,700,000
4,900,000
64.64%
27.07%
There were 5,783,333 unlisted employee share option plan options exercisable at $0.085 each
and expiring on 12 December 2023 held by six holders, on issue.
There were 5,000,000 unlisted options exercisable at $0.093 each and expiring on 1 February 2024
held by one holder, on issue. Details of the holders holding more than 20% of the above:
Bio-Link Australia Pty Ltd
Number of Options
Percentage
5,000,000
100.00%
There were 3,000,000 unlisted options exercisable at $0.10 each and expiring on 4 April 2024 held
by one holder, on issue. Details of the holders holding more than 20% of the above:
Malcolm John McComas
Number of Options
3,000,000
Percentage
100.00%
There were 5,000,000 unlisted options exercisable at $0.10 each and expiring on 24 March 2025
held by one holder, on issue. Details of the holders holding more than 20% of the above:
Geoffrey Edward Duncan Brooke
Number of Options
5,000,000
Percentage
100.00%
There were 1,600,000 unlisted employee share option plan options exercisable at $0.046 each
and expiring on 27 September 2025 held by one holder, on issue.
1.
2.
3.
4.
5.
6.
7.
8.
Restricted Securities
The Company has no securities on issue that are subject to either ASX or voluntary escrow.
On-Market Buy-Back
There is no current on-market buy back in place.
79